Method for providing support to a urethra in treating urinary incontinence

Information

  • Patent Grant
  • 10639138
  • Patent Number
    10,639,138
  • Date Filed
    Tuesday, January 30, 2018
    6 years ago
  • Date Issued
    Tuesday, May 5, 2020
    4 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Lacyk; John P
    Agents
    • Coloplast Corp., Coloplast A/S
    • Baumann; Nick
Abstract
A method for providing support to a urethra in treating urinary incontinence includes passing first and second elongate members coupled to a urethral support through an incision in the vaginal wall, around sides of the urethra and behind a pubic bone. The method includes locating the urethral support under the urethra applying tension to one of the elongate members with a rotary force tensioner and adjusting tension of the urethral support.
Description
TECHNICAL FIELD

This invention relates to a system and method for the treatment of pelvic floor abnormalities, in particular female urinary incontinence.


BACKGROUND OF THE INVENTION

Urinary incontinence is an involuntary release of urine when increases in abdominal pressure caused by sneezing, coughing, or exercising, for example, are not uniformly transmitted to the proximal urethra, resulting in urine “leakage.” Moderate urinary incontinence is inconvenient and can be a social and hygienic problem, while severe urinary incontinence can be disabling. Urinary incontinence occurs in women and is caused by for example, hypermobility of the bladder neck and proximal urethra (excessive downward and rotational movement of the bladder neck) or intrinsic sphincter deficiency.


Urinary incontinence affects a large number of women and, consequently, various approaches have been developed to treat female urinary incontinence. Those skilled in the art will be familiar with approaches ranging from pelvic floor exercises to surgical techniques such as Burch colposuspension and Stamey type endoscopic procedures in which the sutures are placed so as to elevate the bladder neck.


One known procedure positions a support, i.e., a sling loosely under the urethra. It is generally understood that this treatment alleviates urinary incontinence by occluding the mid-urethra (for example at a time of raised abdominal pressure by coughing or the like).


Problems associated with surgical correction of the failed support mechanisms include under-correction or over-correction. The surgeon must determine the degree of support necessary to properly elevate and support the urethra to properly address the urinary incontinence problem. This determination must be made both pre-, intra-, and post-operatively. Too little elevation causes urinary incontinence to remain, although the degree of incontinence may be reduced. Too much elevation can result in voiding dysfunction (reduced capacity or inability to void), leading to prolonged catheterization, and the need for postoperative correction.


The incidence of postoperative urinary retention due to post-operative obstruction can be high at several weeks after surgery, and a number of patients have post-operative urinary retention that persists. Symptomatic detrusor instability represents the bladder's response to increased outlet resistance caused by an improperly tensioned sling. The incidence of post-operative irritative symptoms secondary to detrusor instability can be unacceptably high. Appropriate tensioning of the suburethral support, i.e., sling minimizes persistent incontinence and voiding dysfunction. However, appropriate tensioning during surgery is difficult to assess and frequently is found to be excessive or insufficient once the patient has assumed normal posture and movement post-operatively. Methods and devices for immediate and short term post-operative adjustment of the tension in a suburethral support member, i.e., sling for the treatment of urinary incontinence are needed to mitigate the post-operative complications associated with inappropriate tensioning of the sling.


SUMMARY OF THE INVENTION

One of the problems identified and solved by the invention disclosed herein is that appropriate immediate and short-term post-operative tensioning of a suburethral support in a patient can minimize the discomfort, persistent incontinence and voiding dysfunction that often complicates prior art methods and devices for therapy of pelvic floor abnormalities including urinary incontinence. The invention described below relates to a system and method that permits fine tuning of a urethral support member, i.e., sling tension immediately post-operatively and for days up to a week rather than hours after the sling has been implanted in the patient.


Accordingly, at least one objective according to the invention described herein is to provide a system and method that mitigates the post-operative complications associated with under-tensioning or over-tensioning a suburethral sling implanted for the therapy of urinary incontinence or other pelvic floor dysfunctional or structural abnormalities.


In one aspect, the invention relates to a supplementary stabilization system for stabilizing the urethra. The stabilization system has a first elongate thread member and a second elongate thread member, each elongate thread member comprising an absorbable, flexible material having a length extending from a first end to a second end. In one embodiment, the second end of each thread member is free. The system for stabilizing the urethra also has a first stabilizer and a second stabilizer. In one embodiment, the first stabilizer is joined to the first end of the first elongate thread member. The second stabilizer is joined to the first end of the second elongate member thread member.


In one embodiment, the elongate thread members are non-porous, i.e., having no interstices such as pits, gaps or holes for cellular integration. The width of each elongate thread member is in the range of 0.1 to 2 mm.


The supplementary stabilization system also has a first and second suspending member and a support member. The support member has a first end and a second end. The first suspending member and the second suspending member each have a first end and a second end. The first end of each suspending member is joined to one of the first or second stabilizer. The second end of each suspending member is joined to either the first end or the second end of the support member.


In one embodiment, the support member has a length that is shorter than either of the first and second thread member. In one embodiment, the first thread member and the second thread member have a width that is in the range of about 0.8% to 20% of the width of the support member. Each of the thread first thread member and the second thread member may also have a length that is longer than the support member.


In a particular embodiment, the urethral support system has a tensioner. The tensioner includes a mechanism for including and retaining 1 or 2 thread members and a mechanism for tightening and loosening the urethral support member by mechanically exerting a linear or rotary force movement or by manual means.


In another aspect, the invention relates to a method for stabilizing a urethral support member under the urethra to treat urinary incontinence, for example. According to the method, a surgeon introduces a urethral support stabilization system including an absorbable first elongate member and an absorbable second elongate member having a first end and a second end, and the urethral support member through an incision in the vaginal wall. The first end of the system is introduced to the paraurethral space lateral to the urethra, through the subcutaneous tissue, and through the skin at a first location. The second end of the system is introduced in the paraurethral space on the other side of the urethra, through the subcutaneous tissue on that side of the urethra, and through the skin at a second location. In one embodiment the first and second locations are located on the skin of the abdomen. In another embodiment, the first and second locations are located on the perineal skin or the skin of the upper medial leg.


In an alternative method, the order of tissues through which the urethral support system passes is reverse of the order above.


In one embodiment, the urethral support stabilization system further includes a stabilizer connectable to an elongate member. The method further comprises positioning the stabilizer in soft tissue, for example, in the soft tissue of the retropubic space, the soft tissue of the perineal space, or the pre-pubic soft tissue. The stabilizer is located between an absorbable elongate member and the urethral support member. The length of the urethral support stabilization system between the stabilizer and the midpoint of the urethral support member is less than the distance between the patient's urethra and the skin at the first location. According to the invention, the stabilizer is positioned in pelvic soft tissue without penetrating the rectus sheath, in a vaginal to abdominal approach, or the subcutaneous tissue of the perineal skin in a vaginal to perineal approach or in the subcutaneous tissue of the pre-pubic skin in a vaginal to pre-pubic approach.


In one embodiment, the method of the invention further includes providing a tensioner to the surface of the abdominal perineal, or pre-pubic skin, as the case may be. The tensioner has a first and second end and is joined to the first and second elongate members, respectively, after the elongate members emerge from the skin. The method further includes adjusting the tension on the support member by adjusting the tensioner. At anytime up to ten days after the urethral support member is implanted in the patient, tension is applied to the second end of the elongate member at the first location. In one embodiment, the tension is applied manually by the surgeon. Alternatively, tension may be applied to the elongate member and transmitted to the urethral support member by mechanical means, for example, by a mechanical rotary or a linear force movement. The magnitude of the tension is sufficient to permit a remnant of the first end of the elongate member to retract under the skin after cutting the remnant. The first end of the elongate member is cut while it is under tension wherein the remnant of the first end retracts under the skin.


In one embodiment of the method of the invention, applying tension to one or the other elongate member comprises advancing or withdrawing one or the other stabilizer in the soft tissues of the patient. As used herein, withdrawing a stabilizer in the soft tissues of the patient means moving the stabilizer back along the path in which the stabilizer was advanced, i.e., in a reverse direction, without causing significant trauma to the soft tissue along the path and without applying more force, preferably less force, than the force that was required to advance the stabilizer.


These and other objects, along with advantages and features of the present invention herein disclosed, will become apparent through reference to the following description, the accompanying drawings, and the claims. Furthermore, it is to be understood that the features of the various embodiments described herein are not mutually exclusive and can exist in various combinations and permutations.





BRIEF DESCRIPTION OF THE FIGURES

The foregoing and other objects, features and advantages of the present invention disclosed herein, as well as the invention itself, will be more fully understood from the following description of preferred embodiments and claims, when read together with the accompanying drawings. The drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating the principles of the invention.



FIG. 1 illustrates a plan view of a urethral support system according to an embodiment of the invention;



FIG. 2A illustrates a side view of a first elongate member and a second elongate member of the urethral support system according to an embodiment of the invention;



FIG. 2B illustrates various embodiments of the cross-sectional shape of the first and second elongate members taken at 1B-1B of the urethral support system illustrated in FIG. 1;



FIG. 3A illustrates a front view and FIG. 3B illustrates a perspective view of a stabilizer of the urethral support system according to an embodiment of the invention;



FIG. 4 illustrates a plan view of a urethral support system including a first suspending member and a second suspending member according to another embodiment of the invention;



FIG. 5A illustrates a top view of a urethral support member connected to a stabilizer at each end of the urethral support system according to an embodiment of the invention;



FIG. 5B illustrates a side view of the urethral support member and stabilizer illustrated in FIG. 5A;



FIG. 6A illustrates a top view of a tensioner of the urethral support system according to an embodiment of the invention;



FIG. 6B illustrates a side view of the tensioner illustrated in FIG. 6A;



FIG. 7A illustrates a perspective view of a tensioner of the urethral support system according to another embodiment of the invention;



FIG. 7B illustrates an exploded view of the tensioner illustrated in FIG. 7A;



FIGS. 7C-7E illustrate the steps for applying retaining and applying tension to an elongate member by the tensioner illustrated in FIG. 7A;



FIG. 8A illustrates a sagittal section and FIGS. 8B and 8C illustrate a transverse section of the pelvic area illustrating the steps in a method for treating the pelvic floor, for example, for treating urinary incontinence according to an embodiment of the invention;



FIG. 9A illustrates a sagittal section taken at 9A-9A in FIG. 9B; and



FIG. 9B illustrates a transverse section of the pelvic area illustrating the steps in a method for treating the pelvic floor, for example, for treating urinary incontinence, according to another embodiment of the invention.





DESCRIPTION


FIG. 1 illustrates a urethral support system 20 according to an embodiment of the invention. Referring to FIG. 1, the exemplary urethral support system 20 has multiple components including a supplementary urethral support stabilization system 10 comprising a first elongate member 22 and a second elongate member 22′. In one embodiment of the invention, the supplementary urethral support stabilization system 10 further includes at least one tensioner (not shown), alternatively two tensioners described below. In another embodiment, the supplementary stabilization system 10 includes a first elongate member 22 and a second elongate member 22′, and a first stabilizer 24 and a second stabilizer 24′. Alternatively, the supplementary urethral support stabilization system 10 includes at least one tensioner, a first and second elongate member 22, 22′, and a first and second stabilizer 24, 24′. The urethral support system 20 further includes a support member 26. In one embodiment, the urethral support system 20 further includes a first suspending member 23 and a second suspending member 23′.



FIGS. 2A and 2B illustrate an embodiment of the supplementary urethral support stabilization system 10 of the urethral support system 20 including the first elongate member 22 and the second elongate member 22′. With reference to FIG. 2A, the exemplary first elongate member 22 and the exemplary second elongate member 22′ are substantially identical and typically thread-like, i.e., not tape or ribbon-like members. The material used to make the elongate member is absorbable, i.e., biodegradable and does not act as a scaffold to permit ingrowth of patient tissues, e.g., fibrous tissue, into the material. Appropriate materials include absorbable synthetic polymers, lactide, glycolide, caprolactone, co-polymers or combinations of the above, for example. In one embodiment, the material used to make the elongate member is solid, for example, monofilament without interstices such as pores, pits, or spaces, for example, that would permit cellular integration in the material, i.e., not a mesh, braid, knitted, or woven material. In another embodiment the material may be braided.


Each of the first elongate member 22 and the second elongate member 22′ is longer or as long as the urethral support member 26 (described below in greater detail). Embodiments of the elongate member made from a monofilament lack the projecting ends of mesh, knitted, woven, or braided materials and therefore slide in soft tissue more easily forward (advancing) in one direction or backward (withdrawing) in the opposite direction. In one embodiment, each of the first elongate member 22 and the second elongate member 22′ includes a first end 30 and a second end 32. In one embodiment, the second end 32 is free while the first end 30 is joined to another part of the urethral support system 20.


Referring to FIG. 2B, typically, the first elongate member 22 and second elongate member 22′ of the supplementary urethral support stabilization system 10 have a cross-sectional width in the range of about 0.1 to 2.0 millimeters. The cross-sectional shape of the first 22 and second elongate members 22′ may be round, oval, triangular, or rectangular, for example. In one embodiment, the thread-like elongate members 22, 22′ are sufficiently flexible to be knotted. The elongate members may be coated with an absorbable, i.e., biodegradable lubricious material, for example, proteins, polysaccharides, hydrophilic polymers, wax, hydrogel, silicone, silicone rubber, PTFE, PBA, ethyl cellulose or the like, to ease the sliding of the elongate member in soft tissues. The length of each of the first and second elongate members is in the range for example of about, 6-18 cm, preferably 7-16 cm. The thin, thread-like feature of the elongate member is advantageous over the prior art because the elongate members according to the invention do not permit ingrowth of patient tissue and slide in two-directions, i.e., forward and backward more easily than prior art urethral support sling systems which use broad flat tape-like members to encourage ingrowth of patient tissues and can not be moved without causing significant tissue trauma after operative placement.



FIGS. 3A and 3B illustrate an exemplary stabilizer 24 of the supplementary urethral support stabilization system 10 of the urethral support system 20 according to an embodiment of the invention. Referring to FIG. 3A, the exemplary stabilizer 24 is a planar, elongate, substantially rectangular or oval tab including a radius 51 at the distal end 52, and is flat at the proximal end 54 opposite to the distal end 52. Alternatively, the stabilizer 24 is substantially cylindrical (not shown) rather than planar or the stabilizer 24 may include a radius 51 at the proximal end 54 as well as at the distal end 52. The sides 56 of the stabilizer 24 include multiple radii 53, or flat beads, for example, 2-6 flat beads, more preferably 1-2 flat beads, most preferably one bead, i.e., radius. Other than the “beads”, all sides of the stabilizer are devoid of projections that may increase the drag or prevent substantially free passage of the stabilizer 24 in soft tissue. The length of the stabilizer 24 is in the range of about 0.8 to 2.0 cm. The width of the stabilizer at its widest point is in the range of about 2 to 4 mm, preferably 3 mm. The thickness of the stabilizer is in the range of about 100 to 400 microns, preferably 200 microns.


With continued reference to FIGS. 3A and 3B, in one embodiment of the invention, the illustrated exemplary stabilizer 24 includes a throughhole 58 at the distal end 52 extending from one surface 61 to the other surface 62 of the stabilizer 24. In one embodiment, the throughhole 58 operates as an eyelet to which the first end of the elongate member (not shown) may be knotted to connect the stabilizer to the elongate member. The multiple beads 53 along the sides 56 of the stabilizer 24 permit ratcheting of the stabilizer 24 as it is pulled through the fascia of the patient by the surgeon during implantation of the urethral support system 20 illustrated in FIG. 1. Ratcheting aids the surgeon during the implantation procedure by increasing the “feel” of the system as it is being implanted.


The stabilizer 24 including the beads along the sides, described above, has at least one advantage over prior art stabilizers in that the stabilizer 24 may be reversibly transitioned in tissue, i.e., movement in tissues two-ways: (i) forward along the path of the respective elongate member to which the stabilizer 24 is joined, and (ii) back along the path already taken by the stabilizer 24. Accordingly, the stabilizer 24 permits positional fine-tuning by transitioning the stabilizer 24 forward or backwards, for example, by pulling in either direction during and after delivery of the urethral support system 20 in the patient's tissues. Moreover, the stabilizers of the supplementary stabilization system 10 aid in holding the urethral support member under the urethra in a correct position. In addition, the stabilizers according to the invention are not readily palpable, or may not be palpable transvaginally. The stabilizers and/or the supplementary stabilization system, according to the invention, are positioned in the soft tissue with adequate tensile strength to counter dislodging by, for example, coughing or straining, or by other instances of increased intra-abdominal pressure, until suitable integration of the patient's soft tissue occurs with the implanted urethral support member. Typically, the timeframe required for integration of the urethral support member is about 24 hours to about seven days.


The stabilizer according to the invention differs structurally and functionally from prior art devices because prior art devices are typically pronged, barbed, or have rough surfaces that, once drawn into soft tissue, cannot be withdrawn along the path already taken by the device. In contrast, the stabilizer according to the invention may be withdrawn along the tissue path already taken with minimal trauma to the soft tissue and allows forward and backward repositioning of the urethral support member. In particular, the stabilizer according to the invention permits adjustment to the tension of the urethral support member by transmitting the tension to the urethral support member through the stabilizer after the stabilizer is introduced into the patient's tissues. Because the stabilizer can be moved forward (advanced) and backward (withdrawn), tension transmitted to the urethral support member can be reduced as well as increased, a feature not present in prior art urethral support systems or methods for treating urinary incontinence.


Referring again to FIG. 1, the exemplary first stabilizer 24 is joined to the first end 30 of the first elongate member 22 and the second stabilizer 24′ is joined to the first end 30 of the second elongate member 22′ of the supplementary urethral support stabilization system 10. The stabilizer may be joined to the elongate member by any means known in the art, such as by knotting the elongate member to the stabilizer through the stabilizer throughhole, for example, or by thermal bonding, ultrasonic bonding, application of an adhesive, chemical bonding, or by molding a stabilizer-elongate member combination such that the stabilizer and the elongate member form a single integral part.


Referring to FIG. 4, in one embodiment, the urethral support system 20 further includes a first suspending member 23 and a second suspending member 23′ that connect the first stabilizer 24 to one end of the urethral support member 26, and the second stabilizer 24′ to the other end of the urethral support member, respectively. The suspending members 23 may be for example, a strip, such as, for example, a polymer strip. The suspending members may be joined to the support member 26 and/or the stabilizers 24, 24′ by crimping, thermal bonding, chemical bonding, ultrasonic bonding, adhesive, or formed as an integral unit with the stabilizers and or the urethral support member.


Each of the exemplary first suspending member 23 and second suspending member 23′ illustrated in FIG. 4 feature an elongated element having a length in the range of about 1 to 3 cm, preferably about 1 to 2 cm. The width of each of the suspending members is typically 11 mm on the end adjacent to the mesh tapering to 2 mm on the end adjacent to the stabilizer.


In another embodiment referring again to FIG. 1, the exemplary suspending members 23, 23′ form an integral part of the urethral support member 26 and taper to the stabilizers 24, 24′, respectively. Alternatively, the urethral support member 26 is joined directly to the stabilizers 24, 24′ without an intervening suspending member (see FIGS. 5A-5B).



FIGS. 5A and 5B illustrate a urethral support member 26, such as a sling, according to an embodiment of the invention. The exemplary urethral support member 26 is a flat, ribbon, or tape-like implant. According to one embodiment, the support member 26 is a mesh comprised of strands. The length of the support member 26 is in the range of about, 6 to 20 cm, preferably 7 to 16 cm, more preferably 8 to 14 cm preferably 12 cm, or 8 cm in length. The width of the urethral support member 26 may be in the range of about 6 to 15 mm, preferably 8 to 13 mm, more preferably 11 mm in width. The weight of the urethral support member 26 is in the range of about 10 to 30 g/m2, preferably 15 to 25 g/m2, more preferably 18 to 20 g/m2, most preferably 19 g/m2. Exemplary embodiments of the mesh urethral support member are described in U.S. Ser. Nos. 10/473,825 and 10/398,992, incorporated by reference herein. The strands of the mesh urethral support member 26 are in the range of about 150 to 600 microns in diameter. The strands are arranged such that they form a regular network and are spaced apart from each other such that for a diamond net arrangement a space of between 2 to 5 mm exists between the points where the strands of the mesh interact with each other. In a hexagonal net arrangement the space is between 2 to 5 mm between opposite diagonal points where the strands of the mesh interact.


It is preferable to space the strands as far as part as possible to allow blood to pass through the implant and reduce the mass of the implant, while providing the mesh with sufficient tensile strength and elasticity to be effective. It can therefore be appreciated that considerable variability in the maximum spacing between the strands can be achieved depending on the material from which the strands are comprised and the net pattern in which the strands are arranged.


In one embodiment the strands are arranged in a diamond net pattern, however any pattern which provides suitable tensile strength and elasticity may be used. For example a hexagonal net pattern may be used.


Ideally, in order to reduce the overall mass of the urethral support member, the strands should have as narrow a diameter as possible while still providing the mesh with suitable tensile strength and elasticity. The strands of the mesh include at least two filaments arranged to interact such that pores are formed between the filaments. The pores formed between the filaments are around about 50 to 200 microns, such a spacing allowing fibroblast through growth to occur. Fibroblast through growth secures the implant in place within the body. Additionally and importantly the suitably sized pores allow the implant to act as a scaffold to encourage the deposition of new patient tissue to promote integration of the urethral support member into the patient's soft tissues.


Suitable materials from which the mesh can be made are sufficiently inert to avoid foreign body reactions when retained in the human body for long periods of time and have suitably easy handling characteristics for placement under the urethra in the desired location in the body. The mesh can be easily sterilized to prevent the introduction of infection when the mesh is implanted in the human body.


For example, the filaments may be formed from any biocompatible material. In one embodiment, the filaments are formed from polyester, wherein each polyester filament is around 0.09 mm in diameter. Suitable materials of which the filaments may be formed also include polypropylene.


The filaments of the strands may be knitted together using warp knit to reduce the possibility of fraying of the filaments and strands. The fine warp knit of the filaments provides a urethral support member which is flexible in handling, which can be easily cut into different shapes and dimensions. As the strands are formed using warp knit, the possibility of fraying of the edge of the urethral support member following production or cutting of the mesh is reduced.


Other methods of reducing fraying of the filaments after cutting or production of the mesh include heat treatment, laser treatment or the like to seal the edges of the mesh.


The mesh may be supplied in any shape or size and cut to the appropriate dimensions as required.


It can be appreciated that cutting of the mesh will produce an unfinished edge. Due to the sparse nature of the strands that form the mesh and their narrow diameter, this unfinished edge does not suffer from the same problems as edges of meshes of the prior art.


In other words the edge produced is not rough and jagged such that it increases the likelihood of extrusion of the edge of the mesh in situ or the chance of infection.


An advantage of the mesh of the present invention is that it allows substantially less foreign material to be left into the body than conventional meshes for pelvic region repair.


However, to improve handling the mesh described above may be treated using an absorbable coating. The absorbable coating includes, for example, a layer of absorbable material having a thickness greater than that of the strands of the mesh. For example, the thickness of the layer of absorbable material may be around 1 to 2 mm. The strands of the mesh may be entirely embedded in the absorbable coating such that the outer surface of the mesh is covered entirely of the absorbable coating encasing the entire urethral support member.


Accordingly, in this embodiment, urethral support member has no gaps or holes on its surface to reduce the likelihood of bacteria becoming lodged on the strands of the mesh before implantation of the mesh. Furthermore, the absorbable coating makes the mesh more substantial and less flexible such that it is more easily handled by a surgeon.


In an alternative embodiment, the absorbable coating includes a layer of absorbable material applied to one face of the mesh, such that the mesh has a first face on which the absorbable material has been applied and a second face on which the absorbable material has not been applied such that the first and second faces and each have different characteristics.


It can also be envisaged that the surgical implant is provided with improved surgical handling qualities by a range of other methods. Such methods include the releasable attachment of the mesh to a backing strip.


The backing strip may be formed from plastics material and is adhered to the surgical implant using releasable adhesive.


In a similar fashion to the absorbable coating the backing strip causes the mesh to be more substantial and less flexible such that it is more easily handled by a surgeon. Following the suitable placement of the mesh the backing strip can be removed from the mesh, the mesh being retained in the body and the backing material being removed by the surgeon. Application of the backing strip to the mesh means the mesh benefits from reduced mass but that the mesh and backing strip together give characteristics required for surgical handling.


In a further embodiment, the filaments of the mesh may be comprised from bicomponent microfibres or composite polymers. These technologies provide the implant with dual phase technology.


The bicomponent microfibres comprise a core and surface material. The surface material may be resorbed by host tissues in a matter of hours, while the core material remains in the body for a longer period to enable tissue ingrowth.


Suitable bicomponent microfibres include a polypropylene non-absorable portion and a polylactic acid absorbable portion, for example.


The surface material is present during the surgical procedure when the mesh is being inserted and positioned in the soft tissues of the patient, and provides the mesh with characteristics desirable for surgical handling. Following implantation in the patient's body, typically a few hours, the surface material is absorbed by the body leaving only the core material of the filaments in the body. The core material of the filament has reduced foreign mass in comparison to meshes of the prior art or the mesh when it also includes the surface material.


The mesh of the urethral support member may be formed from composite polymers. As described for the bicomponent microfibres, composite polymers provide the urethral support implants with dual phase technology. A first face of the mesh has particular characteristics such as flexibility and elasticity, while a second face of the mesh provides the mesh with characteristics which improved the surgical handling of the mesh such as strength and robustness. The mesh results in an unfinished edge. This mesh is not as likely to cause the same problems as the rough and jagged edges of the of prior art mesh, due to the fewer strands, smaller diameter filaments and treatment of the mesh with absorbable coating which protects the tissue from the mesh during implantation when damage is most likely to occur.


In a further embodiment, the mesh has perimeter strands. Typically, the mesh is circular or the like in shape and thus the perimeter strand can be generally referred to as a circumferential strand. One strand runs around the circumference of the oval shape of the mesh. In another embodiment, several circumferential strands may be present, each circumferential strand may extend over one side of the oval mesh, i.e. around half the circumference of the mesh. In another embodiment, the circumferential strands arc arranged concentrically and each extends around the mesh at a different radial location.


An outer circumferential strand extending around the perimeter of the mesh, and further circumferential strands are arranged inwardly of the outer circumferential strand forming a perimeter spaced by a distance. The distance between adjacent circumferential members, can vary and in this example is 20 mm.


Transverse strands extend from the centre of the oval mesh to points on the perimeter of the mesh. In this example, four transverse strands are provided across the diameter of the mesh, dividing the mesh into eight angularly equal portions.


The mesh of this embodiment may be formed from materials as previously described. Depending on the material chosen the mesh may be woven, knitted or extruded as one piece, or individual or groups of strands can be extruded separately and joined to one another.


In another embodiment, meshes may have angled sides. A mesh according to this embodiment has a similar structure to that described above. However, the mesh has a perimeter member having angled sides. Further it may have transverse members arranged only to extend towards the perimeter of the mesh, rather than all being across the diameter of the mesh. This provides a more uniform structure. More specifically, the mesh has a transverse member extending along its axis of symmetry, a transverse member bisecting the axis of symmetry, and four further transverse members extending from the axis of symmetry to the perimeter of the mesh.


In addition to the pores provided by the combination of filaments which form the strands, pores can be provided by rings of polypropylene positioned at the intersection of the circumferential and transverse members.


Alternatively the pores may be formed by the spacing of the transverse members, such that pores of a size 50 to 200 microns suitable for enabling tissue ingrowth between the transverse members.


With continued reference to FIGS. 5A and 5B, the urethral support member 26 has a first end 40 and a second end 42. In one embodiment, the length of the urethral support member 26 is shorter than the length of either of the first elongate member 22 and second elongate member 22′. For example, the length of the urethral support member 26 is about 5-100%, preferably about 5-60%, more preferably, 5-30%, most preferably 5-20%, of the length of either the first elongate member 22 or the second elongate member 22′. The width of each elongate member may be in the range of about 0.1-30%, 0.8-20%,1-20%, or 5-10% of the width of the urethral support member, for example.


Referring still to FIGS. 5A and 5B, in one embodiment, the first end 40 of the urethral support member 26 is joined to the first stabilizer 24, and the second end 42 of the urethral support member 26 is joined to the second stabilizer 24′. The end of the support member may be attached to either the first or second stabilizer by ultrasonic welding, thermal bonding, chemical bonding, an adhesive, or by a mechanical means such as, a fastener, a hook and eye, suture, and post and slot, for example. The attachment of the ends of the support member to the first or second stabilizer may be permanent or reversibly attached.


Referring to FIGS. 6A and 6B, in one embodiment according to the invention, the urethral support system 20 further comprises a tensioner 50. Any of the tensioners described herein may be reversibly attached to the patient's skin by, for example, an adhesive.


The exemplary tensioner 50 illustrated in FIGS. 6A and 6B typically is substantially flat to lie close to the skin thereby avoiding being inadvertently dislodged. The shape may be any suitable shape such as round, rectangular or oval as illustrated in FIG. 6A. The length of the tensioner is in the range of about 1 to 6 cm, preferably, 3 to 6 cm, 1 to 3 cm, or 1-4 cm. The width is in the range of about 1 to 4 cm, and the depth is in the range of about 0.5-3 cm.


At each end of the tensioner 50 illustrated in FIGS. 6A and 6B, one hole 52, 52′, more preferably two holes at each end of the tensioner 50, extend from the top surface 56 through the body of the tensioner 50 to the bottom surface 57 of the tensioner 50. The diameter of each hole 52, 52′ is sufficient to easily accommodate the second end 32 of the elongate member 22, 22′ of the supplementary stabilization system 10 of the urethral support system 20. In one embodiment, the diameter of each hole 52, 52′ is in the range of about 5 mm or less, preferably 3 mm. A plurality of smaller diameter holes 54, 54′, for example, linearly arranged at each end of the tensioner 50, extend from the top surface 56, through the body of the tensioner to the bottom surface 57 on both ends of the tensioner 50. The diameter of holes 54, 54′ is smaller than holes 52, 52′ to allow for pinching or clamping of the second end of the elongate member 22, 22′ when the elongate member is pulled from its emergence through the larger holes 52, 52′ at the top surface 56 of the tensioner 50 over to the smaller holes 54, 54′ thereby pinching, cleating or clamping the second end 32 of the elongate member 22 to the tensioner 50.


As an alternative to the embodiment of the tensioner 50 described above, an adhesive may be used alone or in concert with the holes for attaching the second end 32 of the elongate member 22 to the tensioner 50. In yet another embodiment, the tensioner 50 may include only one hole 52.


Referring to FIGS. 7A-7C, in an alternate embodiment, the tensioner comprises a rotary device to provide mechanical advantage by rotary force movement for adjusting the tension on the suburethral support member. The illustrative rotary force tensioner 60 illustrated in an assembled configuration in FIG. 7A and in an exploded format in FIG. 7B, includes a wheel 62 and a wheel ratchet 63. The wheel 62 rotatably locks into the wheel ratchet 63 by, for example, a clip 64, preferably two clips 64, located opposite to one another on the rim 65 of the wheel ratchet 63. At least one ridge 66 perpendicular to the long axis of the wheel ratchet 63 is positioned on the clip 64 and projects towards the center of the wheel ratchet 63.


Referring now to FIGS. 7C-E, the wheel 62 includes at least one gate 67 located on the perimeter of the wheel 62. The gate 67 is a partially detached wedge-like portion of the outer rim 70 of the wheel 62. The second end 32 of the elongate member 22 passes between the gate 67 and the inner rim 68 of the wheel 62. As the wheel 62 is manually rotatably ratcheted on the wheel ratchet 63 by rotating the knob 71 indicated by arrow 69 in FIG. 7D, the gate 67 is compressed by the ridge 66 against the inner rim 68 and the elongate member 22 is locked within the tensioner 50 between the gate 67 and the inner rim 68 of the wheel 62 as illustrated in FIG. 7E.


In one aspect, the invention relates to a kit for treatment of urinary incontinence. In one embodiment, the kit includes a urethral support stabilization system. The urethral support stabilization system includes a first and second elongate member, a first and second stabilizer and optionally a urethral support member, for example a mesh sling. In one embodiment, each of the elongate members comprise an absorbable, non-porous material, without interstices that would permit cellular ingrowth. In another embodiment, each of the stabilizers comprise a substantially planar member with multiple radii, i.e., beads as described above projecting from the edge of the planar surface. The stabilizer may further feature a throughhole at one end. In another embodiment, the kit of the invention may further include a tensioner including a hole for pinching the end of an elongate member or an adhesive for adhering to an elongate member.


In another aspect, the invention relates to a method for providing urethral support in a patient, such as, for the therapy of female urinary incontinence, and/or uterovaginal prolapse, for example. Referring to FIGS. 8A to 8C, in one embodiment of the method of the invention, a surgeon takes a vaginal to abdominal skin approach by incising the vaginal wall 108 to provide a site for the introduction of the urethral support system 20, described above, to the para-urethral area, i.e., adjacent to the urethra. The supplementary stabilization system 10 including the first elongate member 22 led by the second 32 or free end, is passed through the vaginal incision, around one side of the urethra 114, through the soft tissue of the retro-pubic space 112, behind the pubic bone 102, through the rectus sheath 104, subcutaneous tissue 118, and abdominal skin 106 to emerge on the surface of the abdominal skin 106 at a first abdominal location. According to one embodiment, the first end 30 of the first elongate member 22 of the supplementary stabilization system 10 is pre-attached to the first stabilizer 24. Alternatively, the first end 30 of the first elongate member 22 of the supplementary stabilization system 10 is attached to the first stabilizer 24 during the surgical procedure. In yet another embodiment, the elongate member and stabilizer are detachable.


In one embodiment, the first stabilizer 24 is positioned in the soft tissue of the retropubic space 112, while the elongate member 22 emerges from the abdominal skin 106. The first stabilizer 24 is positioned in the retropubic space, i.e., it does not pass through any of the intervening tissues i.e., rectus sheath, subcutaneous tissue and skin, between the retropubic space and the skin surface.


The first end 40 of the urethral support member 26 is pre-attached to the first stabilizer 24. Alternatively, the first end 40 of the urethral support member 26 is attachable and detachable to the first stabilizer 24 during the surgical procedure. A portion of the urethral support member 26, for example, a first portion extending from approximately the mid-point to one end of the urethral support member, is positioned on the side of the urethra 114 through which the first elongate member 22 passed.


This procedure is repeated with the second elongate member 22′, second stabilizer 24′, and the support member 26 on the other side of the urethra 114. As with the first stabilizer 24, the second stabilizer 24′ is positioned in the retropubic space but at a location different than the first stabilizer 24. The second stabilizer 24′ does not pass through any of the intervening tissues i.e., rectus sheath, subcutaneous tissue and skin, between the retropubic space and the skin surface. Following introduction of the second elongate member 22′ and the second stabilizer 24′, the remaining urethral support member 26 is positioned under the urethra 114 with one end of the support member on one side of the urethra 114 and the other end of the support member on the other side of the urethra 114.


In one embodiment, the first stabilizer 24 and the second stabilizer 24′ cannot extend into the intervening tissues between the retropubic space and the skin surface largely because the length of the urethral support member 26 from its midpoint under the urethra to one end of the urethral support member and the length of the suspending member, if one is used, that is positioned on one side of the urethral support member to which the stabilizer is connected, is shorter than the distance between the urethra and the rectus sheath.


Referring to FIG. 8B, following the emergence of the second elongate member 22′ at a second abdominal location, the position of the urethral support member 26 under the urethra is adjusted and stabilized by applying tension via the supplementary stabilization system 10 to one, the other, or both of the first 22 elongate member and second elongate member 22′. Tension may be applied manually, i.e., by hand without mechanical aids or by a system that includes mechanical aids such as by mechanically applying rotary or linear force movement, and, further, may measure and or regulate the applied tension. The tension is transmitted from the elongate members to the first and second stabilizers 24, 24′. For example, by applying tension such as by pulling the first elongate member 22 at its second end 32, the first stabilizer 24 advances through the soft tissue while the second stabilizer 24′ is withdrawn through the soft tissue along the path already taken by the second stabilizer 24′.


Referring to FIG. 8C, in one embodiment of the method of the invention, the supplementary stabilization system 10 further includes the tensioner 50, such as the tensioner 50 described above with respect to FIGS. 6A and 6B. The exemplary tensioner 50 is joined to the free ends 32, 32′ of the first and second elongate members 22, 22′, respectively, emerging through, for example, the abdominal skin 106. The tension of the urethral support member 26 is adjusted by applying tension to the second end 32, 32′, respectively, of the first and second elongate members 22, 22′. The urethral support member 26 may be moved from side-to-side because the stabilizer 24, 24′, illustrated in FIGS. 3A and 3B, may be pulled back and forth in the soft tissues in contrast to prior art devices which have prongs, hooks, barbs or other obtrusive projections to prevent the device from being withdrawn from the soft tissue along the path of entry.


In another embodiment, the surgeon takes a vaginal to perineal approach. The perineum corresponds to the outlet of the pelvis inferior to the pelvic diaphragm (levator ani and coccygeus). The boundaries of the perineum are provided by the pubic arch and the arcuate ligament of the pubis, the tip of the coccyx and on either side of the inferior rami of the pubis and ischium, and the sacrotuberous ligament. A line joining the anterior parts of the ischial tuberosities divides the perineum into two portions, the posterior anal triangle portion and the smaller anterior urogenital triangle.


In the vaginal to perineal approach, referring now to FIGS. 9A and 9B, a surgeon incises the vaginal wall 108 to provide a site for the introduction of the urethral support system 20, described above, to the para-urethral area. The supplementary stabilization system 10 including the first elongate member 22 led by the second 32 or free end, is passed through the vaginal incision, around one side of the urethra 114, through the soft tissues of the perineal space 110 including the perineal muscles and towards and behind the inferior pubic ramus, but not through the obturator foramen, through the subcutaneous tissue underlying the skin of the perineum 150, emerging on the surface of the perineal skin 150 at a first perineal location.


The first stabilizer 24 is positioned in the soft tissues of the perineal space 110 while the elongate member 22 emerges from the perineal skin 150. The first stabilizer 24 is positioned in the soft tissue of the perineal space 110, i.e., the first stabilizer 24 does not pass through the skin.


The first end 40 of the support member 26 is pre-attached to the first stabilizer 24. Alternatively, the first end 40 of the support member 26 is attachable and detachable to the first stabilizer 24 during the surgical procedure. The support member 26 is positioned on the side of the urethra 114 through which the first elongate member 22 passed.


Referring to FIG. 9B, this procedure is repeated with the second elongate member 22′, second stabilizer 24′ and the support member 26 on the other side of the urethra 114. As with the first stabilizer 24, the second stabilizer 24′ is positioned in the perineal space 110 at a location different than the first stabilizer 24. The second stabilizer 24′ does not pass through the skin. Neither the first stabilizer 24 nor the second stabilizer 24′ are positioned at a location above the endopelvic fascia. Moreover, the urethral support system used for a vaginal to perineal approach does not extend through the abdominal wall or the obturator foramen. Following introduction of the second elongate member 22′ and the second stabilizer 24′, the urethral support member 26 is positioned under the urethra 114 with one end of the urethral support member 26 on one side of the urethra 114 and the other end of the urethral support member 26 on the other side of the urethra 114.


In one embodiment, the first stabilizer 24 and the second stabilizer 24′ cannot extend into the intervening tissue between the perineal space and the skin surface because the length of the urethral support member from its midpoint on one side of the urethra to one end of then urethral support member and the length of the suspending member, if one is used, is less than the distance between the urethra and the perineal skin. Typically, for the vaginal to perineal approach the length of the urethral support member from its midpoint on one side of the urethra and the suspending member on the same side of the urethra, if one is used, is in the range of about 3 to 6 cm, preferably 4 cm.


Following the emergence of the second elongate member 22′ at a second perineal skin location, the position of the urethral support member 26 under the urethra is adjusted and stabilized by applying tension to one or the other of the first 22 and second elongate member 22′, or both. Tension may be applied manually, i.e., by hand without mechanical aids or by a system that includes mechanical aids such as by mechanically applying rotary or linear force movement, and further, may measure and or regulate the applied tension. As discussed above, the tension is transmitted from the elongate members to the first and second stabilizers 24, 24′. For example, applying tension such as by pulling the second end 32 of the first elongate member 22, the first stabilizer 24 advances through the soft tissue while the second stabilizer 24′ is withdrawn through the soft tissue along the path already taken by the second stabilizer 24′.


A first tensioner 50 is joined to the free end 32 of the first elongate member 22 of the supplementary stabilization system 10 that emerges through the perineal skin at a first location. A second tensioner 50 is joined to the free end 32′ of the second elongate member 22′ of the supplementary stabilization system 10 emerging through the perineal skin at a second location. The tension of the urethral support member 26 is adjusted by applying tension to the first elongate member 22 and the second elongate member 22′.


In one embodiment, the skin locations may be on the medial aspect of the thighs.


In another embodiment of the method of the invention, the stabilizers 24, 24′ are positioned in the pre-pubic soft tissue and the ends 32 of the first and second elongate members 22, 22′ emerge through the pre-pubic skin.


Alternatively, the route through tissues can be reversed, for example, for an abdominal to vaginal approach, the urethral support system would pass through tissues in the following order, abdominal skin at a first location, subcutaneous tissue, rectus sheath, retropubic space, suburethral space, and finally, through the vaginal incision. These steps would be repeated on the other side starting at a second abdominal skin location.


For a perineal to vaginal approach, the urethral system would pass through tissues in the following order, perineal skin at a first location, subcutaneous perineal tissue, perineal muscles, suburethral space and finally through a vaginal incision. The steps would be repeated on the other side starting at a second perineal skin location.


Regardless of the surgical approach, according to the invention, intra-operative and post operative adjustment of the urethral support member, for example by adjusting the tension applied to the urethral support member, may be performed for up to one week, preferably 72 hours after surgery. For example, in one embodiment of the method, the tensioner 50 is left in place for 1 to 7 days following implantation of the urethral support member 26. The ends 32 of the first and second elongate members 22, 22′ emerging through the abdominal wall, perineal skin, or pre-pubic skin as the case may be, are transected after first applying tension to the free ends 32, 32′ to pull a portion of the elongate members 22, 22′ adjacent to the free end from below the skin, through the skin, to the skin surface. The portion of the elongate member that was below the skin is cut so that the remnant of the elongate member after cutting that was under tension retracts back under the skin. The same procedure is repeated with the elongate member emerging at the second abdominal, perineal, or pre-pubic location, as the case may be. The one or more tensioners are removed from the patient.


In a particular embodiment of the method of the invention, the vaginal incision is closed, e.g., by suturing followed by adjustment of the tension of the urethral support member by transmitting tension from the elongate members through the stabilizers to the urethral support member.

Claims
  • 1. A method for providing support to a urethra in treating urinary incontinence, the method comprising: forming an incision in a vaginal wall and opening a site for introduction of a urethral support;passing a first elongate member coupled to the urethral support through the incision in the vaginal wall, around a first side of the urethra and through tissue of a retro-pubic space on a first path behind a pubic bone, and through a rectus sheath and a surface of abdominal skin arriving at a first abdominal location;passing a second elongate member coupled to the urethral support through the incision in the vaginal wall, around a second side of the urethra and through tissue of the retro-pubic space on a second path behind the pubic bone, and through the rectus sheath and the surface of abdominal skin arriving at a second abdominal location;locating the urethral support under the urethra;coupling a rotary force tensioner to at least one of the first elongate member and the second elongate member; andapplying tension to the at least one of the first elongate member and the second elongate member with the rotary force tensioner and adjusting tension of the urethral support.
  • 2. The method of claim 1, comprising post-operatively adjusting tension of the urethral support one day after implantation of the urethral support.
  • 3. The method of claim 1, comprising post-operatively adjusting tension of the urethral support 72 hours after implantation of the urethral support.
  • 4. The method of claim 1, where the rotary force tensioner includes a wheel engaged with a wheel ratchet, the method further comprising: engaging the at least one of the first elongate member and the second elongate member with the wheel; androtating the wheel relative to the wheel ratchet and imparting force to the at least one of the first elongate member and the second elongate member.
  • 5. The method of claim 1, comprising locating the rotary force tensioner over the rectus sheath.
  • 6. The method of claim 1, comprising sliding the at least one of the first elongate member and the second elongate member in one of two directions including a first direction from the urethral support toward the surface of abdominal skin and a second direction from the surface of abdominal skin toward the urethral support.
  • 7. The method of claim 1, further comprising fine-tuning tension applied to the urethral support.
  • 8. The method of claim 1, further comprising regulating tension applied to one of the first elongate member and the second elongate member.
  • 9. The method of claim 1, comprising post-operatively adjusting tension of the urethral support by loosening one of the first elongate member and the second elongate member.
  • 10. A method for providing support to a urethra in treating urinary incontinence, the method comprising: forming an incision in a vaginal wall, with the incision sized for introduction of a urethral support into a body of a patient;passing a first elongate member coupled to the urethral support through the incision in the vaginal wall, around a first side of the urethra, and along a first path behind a pubic bone and through a rectus sheath and a surface of abdominal skin;passing a second elongate member coupled to the urethral support through the incision in the vaginal wall, around a second side of the urethra, and along a second path behind the pubic bone and through the rectus sheath and the surface of abdominal skin;positioning the urethral support under the urethra;providing a rotary force tensioner having a rotating wheel and coupling one of the first elongate member and the second elongate member to the rotating wheel; andturning the rotating wheel and applying tension to at least one of the first elongate member and the second elongate member.
  • 11. The method of claim 1, further comprising fine-tuning tension applied to the urethral support more than one day after implantation of the urethral support into the body of the patient.
  • 12. The method of claim 1, comprising post-operatively adjusting tension to at least one of the first elongate member and the second elongate member after implantation of the urethral support into the body of the patient.
  • 13. The method of claim 1, comprising manually turning the rotating wheel and applying tension to at least one of the first elongate member and the second elongate member.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 14/740,276 filed Jun. 16, 2015, which is a continuation of U.S. Ser. No. 14/151,873 filed Jan. 10, 2014 and now issued as U.S. Pat. No. 9,089,394, which is a continuation of U.S. application Ser. No. 13/402,978 filed Feb. 23, 2012 and now issued as U.S. Pat. No. 8,668,635, which is a continuation of U.S. application Ser. No. 12/072,901 filed Feb. 28, 2008 and now issued as U.S. Pat. No. 8,167,785. Priority to each of the foregoing is claimed.

US Referenced Citations (500)
Number Name Date Kind
1450101 Mathewson Mar 1923 A
2097018 Chamberlin Oct 1937 A
2427176 Aldeen Sep 1947 A
2738790 Todt Sr. et al. Mar 1956 A
3054406 Usher Sep 1962 A
3124136 Usher Mar 1964 A
3126600 De Marre Mar 1964 A
3182662 Shirodkar May 1965 A
3311110 Singerman et al. Mar 1967 A
3384073 Van Winkle, Jr. May 1968 A
3472232 Pendleton Oct 1969 A
3580313 McKnight May 1971 A
3763860 Clarke Oct 1973 A
3789828 Schulte Feb 1974 A
3858783 Kapitanov et al. Jan 1975 A
3888975 Ramwell Jun 1975 A
3911911 Scommegna Oct 1975 A
3913179 Rhee Oct 1975 A
3913573 Gutnick Oct 1975 A
3916899 Theeuwes et al. Nov 1975 A
3924633 Cook et al. Dec 1975 A
3993058 Hoff Nov 1976 A
3995619 Glatzer Dec 1976 A
4019499 Fitzgerald Apr 1977 A
4037603 Wendorff Jul 1977 A
4128100 Wendorff Dec 1978 A
4172458 Pereyra Oct 1979 A
4233968 Shaw, Jr. Nov 1980 A
4235238 Ogiu et al. Nov 1980 A
4246660 Wevers Jan 1981 A
4409866 McBride Oct 1983 A
4441497 Paudler Apr 1984 A
4444933 Columbus et al. Apr 1984 A
4452245 Usher Jun 1984 A
4509516 Richmond Apr 1985 A
4632100 Somers et al. Dec 1986 A
4633873 Dumican et al. Jan 1987 A
4646731 Brower Mar 1987 A
4655221 Devereux Apr 1987 A
4769038 Bendavid et al. Sep 1988 A
4775380 Seedhom et al. Oct 1988 A
4784139 Demos Nov 1988 A
4799484 Smith et al. Jan 1989 A
4857041 Annis et al. Aug 1989 A
4865031 O'Keeffe Sep 1989 A
4873976 Schreiber Oct 1989 A
4911164 Roth Mar 1990 A
4920986 Biswas May 1990 A
4938760 Burton et al. Jul 1990 A
5004468 Atkinson Apr 1991 A
5013292 Lemay May 1991 A
5053043 Gottesman et al. Oct 1991 A
5085661 Moss Feb 1992 A
5112344 Petros May 1992 A
5123428 Schwarz Jun 1992 A
5123910 McIntosh Jun 1992 A
5149329 Richardson Sep 1992 A
5188636 Fedotov Feb 1993 A
5207694 Broome May 1993 A
5209756 Seedhom et al. May 1993 A
5219352 Atkinson Jun 1993 A
5234436 Eaton et al. Aug 1993 A
5250033 Evans et al. Oct 1993 A
5256133 Spitz Oct 1993 A
5259835 Clark et al. Nov 1993 A
5281237 Gimpelson Jan 1994 A
5306279 Atkinson Apr 1994 A
5328077 Lou Jul 1994 A
5336239 Gimpelson Aug 1994 A
5337736 Reddy Aug 1994 A
5342376 Ruff Aug 1994 A
5356432 Rutkow et al. Oct 1994 A
5362294 Seitzinger Nov 1994 A
5368595 Lewis Nov 1994 A
5383904 Totakura et al. Jan 1995 A
5386836 Biswas Feb 1995 A
5397353 Oliver et al. Mar 1995 A
5403328 Shallman Apr 1995 A
5413598 Moreland May 1995 A
5434146 Labrie et al. Jul 1995 A
5439467 Benderev et al. Aug 1995 A
5456711 Hudson Oct 1995 A
5473796 Fusillo Dec 1995 A
5474543 McKay Dec 1995 A
5486197 Le et al. Jan 1996 A
5507754 Green et al. Apr 1996 A
5507796 Hasson Apr 1996 A
5520700 Beyar et al. May 1996 A
5522896 Prescott Jun 1996 A
5544664 Benderev et al. Aug 1996 A
5549619 Peters et al. Aug 1996 A
5562685 Mollenauer et al. Oct 1996 A
5562689 Green et al. Oct 1996 A
5569273 Titone et al. Oct 1996 A
5571139 Jenkins, Jr. Nov 1996 A
5591163 Thompson Jan 1997 A
5611515 Benderev et al. Mar 1997 A
5628756 Barker, Jr. et al. May 1997 A
5633286 Chen May 1997 A
5645568 Chervitz et al. Jul 1997 A
5647836 Blake, III et al. Jul 1997 A
5655270 Boisvert Aug 1997 A
5669935 Rosenman et al. Sep 1997 A
5683349 Makower et al. Nov 1997 A
5689860 Matoba et al. Nov 1997 A
5693072 McIntosh Dec 1997 A
5695525 Mulhauser et al. Dec 1997 A
5697931 Thompson Dec 1997 A
5697978 Sgro Dec 1997 A
5720766 Zang et al. Feb 1998 A
5749884 Benderev et al. May 1998 A
5766221 Benderev et al. Jun 1998 A
5774994 Stein et al. Jul 1998 A
5807403 Beyar et al. Sep 1998 A
5816258 Jervis Oct 1998 A
5830220 Wan et al. Nov 1998 A
5836314 Benderev et al. Nov 1998 A
5836315 Benderev et al. Nov 1998 A
5840011 Landgrebe et al. Nov 1998 A
5842478 Benderev et al. Dec 1998 A
5851229 Lentz et al. Dec 1998 A
5860425 Benderev et al. Jan 1999 A
5899909 Claren et al. May 1999 A
5904692 Steckel et al. May 1999 A
5919232 Chaffringeon et al. Jul 1999 A
5922026 Chin Jul 1999 A
5934283 Willem et al. Aug 1999 A
5935122 Fourkas et al. Aug 1999 A
5944732 Raulerson et al. Aug 1999 A
5954057 Li Sep 1999 A
5971967 Willard Oct 1999 A
5972000 Beyar et al. Oct 1999 A
5988171 Sohn et al. Nov 1999 A
5990378 Ellis Nov 1999 A
5997554 Thompson Dec 1999 A
6005191 Tzeng et al. Dec 1999 A
6010447 Kardjian Jan 2000 A
6030393 Corlew Feb 2000 A
6031148 Hayes et al. Feb 2000 A
6039686 Kovac Mar 2000 A
6042534 Gellman et al. Mar 2000 A
6042536 Tihon et al. Mar 2000 A
6042583 Thompson et al. Mar 2000 A
6048306 Spielberg Apr 2000 A
6048351 Gordon et al. Apr 2000 A
6050937 Benderev Apr 2000 A
6053935 Brenneman et al. Apr 2000 A
6056688 Benderev et al. May 2000 A
6063094 Rosenberg May 2000 A
6068591 Bruckner et al. May 2000 A
6071290 Compton Jun 2000 A
6074341 Anderson et al. Jun 2000 A
6077216 Benderev et al. Jun 2000 A
6090116 D'Aversa et al. Jul 2000 A
6106545 Egan Aug 2000 A
6110101 Tihon et al. Aug 2000 A
6117067 Gil Vernet Sep 2000 A
6159207 Yoon Dec 2000 A
6162962 Hinsch et al. Dec 2000 A
6168611 Rizvi Jan 2001 B1
6174329 Callol et al. Jan 2001 B1
6190401 Green et al. Feb 2001 B1
6197036 Tripp et al. Mar 2001 B1
6200330 Benderev et al. Mar 2001 B1
6221005 Bruckner et al. Apr 2001 B1
6221060 Willard Apr 2001 B1
6231496 Wilk et al. May 2001 B1
6245082 Gellman et al. Jun 2001 B1
6264676 Gellman et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6273852 Lehe et al. Aug 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6292700 Morrison et al. Sep 2001 B1
6302840 Benderev Oct 2001 B1
6306079 Trabucco Oct 2001 B1
6319264 Tormala et al. Nov 2001 B1
6328686 Kovac Dec 2001 B1
6328744 Harari et al. Dec 2001 B1
6334446 Beyar Jan 2002 B1
6336731 Chien Jan 2002 B1
6352553 van der Burg et al. Mar 2002 B1
6355065 Gabbay Mar 2002 B1
6382214 Raz et al. May 2002 B1
6387041 Harari et al. May 2002 B1
6406423 Scetbon Jun 2002 B1
6406480 Beyar et al. Jun 2002 B1
6408656 Ory et al. Jun 2002 B1
6418930 Fowler Jul 2002 B1
6440154 Gellman et al. Aug 2002 B2
6443964 Ory et al. Sep 2002 B1
6461332 Mosel et al. Oct 2002 B1
6475139 Miller Nov 2002 B1
6478727 Scetbon Nov 2002 B2
6478791 Carter et al. Nov 2002 B1
6482214 Sidor, Jr. et al. Nov 2002 B1
6491703 Ulmsten Dec 2002 B1
6494887 Kaladelfos Dec 2002 B1
6494906 Owens Dec 2002 B1
6502578 Raz et al. Jan 2003 B2
6506190 Walshe Jan 2003 B1
6527802 Mayer Mar 2003 B1
6530943 Hoepffner et al. Mar 2003 B1
6544273 Harari et al. Apr 2003 B1
6575897 Ory et al. Jun 2003 B1
6575998 Beyar Jun 2003 B2
6582443 Cabak et al. Jun 2003 B2
6592515 Thierfelder et al. Jul 2003 B2
6596001 Stormby et al. Jul 2003 B2
6599235 Kovac Jul 2003 B2
6599318 Gabbay Jul 2003 B1
6599323 Melican et al. Jul 2003 B2
6612977 Staskin et al. Sep 2003 B2
6638210 Berger Oct 2003 B2
6638211 Suslian et al. Oct 2003 B2
6638284 Rousseau et al. Oct 2003 B1
6641524 Kovac Nov 2003 B2
6641525 Rocheleau et al. Nov 2003 B2
6652450 Neisz et al. Nov 2003 B2
6652595 Nicolo Nov 2003 B1
6666817 Li Dec 2003 B2
6669706 Schmitt et al. Dec 2003 B2
6669735 Pelissier Dec 2003 B1
6673010 Skiba et al. Jan 2004 B2
6675483 Bond et al. Jan 2004 B2
6679896 Gellman et al. Jan 2004 B2
6689047 Gellman Feb 2004 B2
6691711 Raz et al. Feb 2004 B2
6695855 Gaston Feb 2004 B1
6702827 Lund et al. Mar 2004 B1
6737371 Planck et al. May 2004 B1
6755781 Gellman Jun 2004 B2
6764474 Nielsen et al. Jul 2004 B2
6783554 Amara et al. Aug 2004 B2
6786861 Pretorius Sep 2004 B1
6830052 Carter et al. Dec 2004 B2
6860887 Frankle Mar 2005 B1
6878756 Cinelli et al. Apr 2005 B2
6884212 Thierfelder et al. Apr 2005 B2
6911003 Anderson et al. Jun 2005 B2
6932759 Kammerer et al. Aug 2005 B2
6936052 Gellman et al. Aug 2005 B2
6953428 Gellman et al. Oct 2005 B2
6960160 Browning Nov 2005 B2
7025063 Snitkin et al. Apr 2006 B2
7063716 Cunningham Jun 2006 B2
7070556 Anderson et al. Jul 2006 B2
7070558 Gellman et al. Jul 2006 B2
7087065 Ulmsten et al. Aug 2006 B2
7094199 Petros et al. Aug 2006 B2
7112171 Rocheleau et al. Sep 2006 B2
7112210 Ulmsten et al. Sep 2006 B2
7131943 Kammerer Nov 2006 B2
7131944 Jacquetin Nov 2006 B2
7140956 Korovin et al. Nov 2006 B1
7156858 Schuldt Hempe et al. Jan 2007 B2
7204802 De Leval Apr 2007 B2
7229404 Bouffier Jun 2007 B2
7288063 Petros et al. Oct 2007 B2
7290410 Meneghin et al. Nov 2007 B2
7297102 Smith et al. Nov 2007 B2
7326213 Benderev et al. Feb 2008 B2
7347812 Mellier Mar 2008 B2
7371245 Evans et al. May 2008 B2
7387634 Benderev Jun 2008 B2
7395822 Burton et al. Jul 2008 B1
7404819 Darios et al. Jul 2008 B1
7410460 Benderev Aug 2008 B2
7500945 Cox et al. Mar 2009 B2
7517313 Thierfelder et al. Apr 2009 B2
7527633 Rioux May 2009 B2
7559885 Merade et al. Jul 2009 B2
7594921 Browning Sep 2009 B2
7601118 Smith et al. Oct 2009 B2
7611454 De Leval Nov 2009 B2
7614258 Cherok et al. Nov 2009 B2
7621864 Suslian et al. Nov 2009 B2
7628156 Astani et al. Dec 2009 B2
7673631 Astani et al. Mar 2010 B2
7686760 Anderson et al. Mar 2010 B2
7691050 Gellman et al. Apr 2010 B2
7713188 Bouffier May 2010 B2
7722528 Arnal et al. May 2010 B2
7740576 Hodroff et al. Jun 2010 B2
7766926 Bosley, Jr. et al. Aug 2010 B2
7789821 Browning Sep 2010 B2
7794385 Rosenblatt Sep 2010 B2
7815662 Spivey et al. Oct 2010 B2
7927342 Rioux Apr 2011 B2
7975698 Browning Jul 2011 B2
7981022 Gellman et al. Jul 2011 B2
8007430 Browning Aug 2011 B2
8016741 Weiser et al. Sep 2011 B2
8016743 Maroto Sep 2011 B2
8047983 Browning Nov 2011 B2
8092366 Evans Jan 2012 B2
8097007 Evans et al. Jan 2012 B2
8100924 Browning Jan 2012 B2
8118727 Browning Feb 2012 B2
8118728 Browning Feb 2012 B2
8123673 Browning Feb 2012 B2
8128554 Browning Mar 2012 B2
8157821 Browning Apr 2012 B2
8157822 Browning Apr 2012 B2
8162818 Browning Apr 2012 B2
8167785 Browning May 2012 B2
8182412 Browning May 2012 B2
8182413 Browning May 2012 B2
8182545 Cherok et al. May 2012 B2
8215310 Browning Jul 2012 B2
8273011 Browning Sep 2012 B2
8449450 Browning May 2013 B2
8454492 Browning Jun 2013 B2
8469875 Suslian et al. Jun 2013 B2
8469877 Browning Jun 2013 B2
8512223 Browning Aug 2013 B2
8574148 Browning et al. Nov 2013 B2
8603119 Browning Dec 2013 B2
8603120 Browning Dec 2013 B2
8632554 Browning Jan 2014 B2
8668635 Browning Mar 2014 B2
8709471 Browning Apr 2014 B2
8801596 Browning Aug 2014 B2
8821369 Browning Sep 2014 B2
8821370 Browning Sep 2014 B2
8852075 Browning Oct 2014 B2
9005222 Evans et al. Apr 2015 B2
20010000533 Kovac Apr 2001 A1
20010018549 Scetbon Aug 2001 A1
20010039423 Skiba et al. Nov 2001 A1
20010049467 Lehe et al. Dec 2001 A1
20010049538 Trabucco Dec 2001 A1
20010051815 Esplin Dec 2001 A1
20010053916 Rioux Dec 2001 A1
20020005204 Benderev et al. Jan 2002 A1
20020007222 Desai Jan 2002 A1
20020022841 Kovac Feb 2002 A1
20020028980 Thierfelder et al. Mar 2002 A1
20020042658 Tyagi Apr 2002 A1
20020049503 Milbocker Apr 2002 A1
20020052612 Schmitt et al. May 2002 A1
20020052653 Durgin May 2002 A1
20020052654 Darois et al. May 2002 A1
20020055748 Gellman et al. May 2002 A1
20020058959 Gellman May 2002 A1
20020068948 Stormby et al. Jun 2002 A1
20020072694 Snitkin et al. Jun 2002 A1
20020077526 Kammerer et al. Jun 2002 A1
20020078964 Kovac et al. Jun 2002 A1
20020082619 Cabak et al. Jun 2002 A1
20020083949 James Jul 2002 A1
20020091298 Landgrebe Jul 2002 A1
20020091373 Berger Jul 2002 A1
20020099258 Staskin et al. Jul 2002 A1
20020099259 Anderson et al. Jul 2002 A1
20020099260 Suslian et al. Jul 2002 A1
20020103542 Bilbo Aug 2002 A1
20020107430 Neisz et al. Aug 2002 A1
20020107525 Harari et al. Aug 2002 A1
20020115906 Miller Aug 2002 A1
20020119177 Bowman et al. Aug 2002 A1
20020128670 Ulmsten et al. Sep 2002 A1
20020138025 Gellman et al. Sep 2002 A1
20020147382 Neisz et al. Oct 2002 A1
20020151762 Rocheleau et al. Oct 2002 A1
20020151909 Gellman et al. Oct 2002 A1
20020151910 Gellman et al. Oct 2002 A1
20020156487 Gellman et al. Oct 2002 A1
20020156488 Gellman et al. Oct 2002 A1
20020161382 Neisz et al. Oct 2002 A1
20020183588 Fierro Dec 2002 A1
20020188169 Kammerer et al. Dec 2002 A1
20020188301 Dallara et al. Dec 2002 A1
20030004395 Therin Jan 2003 A1
20030009181 Gellman et al. Jan 2003 A1
20030023136 Raz et al. Jan 2003 A1
20030023137 Gellman Jan 2003 A1
20030023138 Luscombe Jan 2003 A1
20030036676 Scetbon Feb 2003 A1
20030050530 Neisz et al. Mar 2003 A1
20030065246 Inman et al. Apr 2003 A1
20030065402 Anderson et al. Apr 2003 A1
20030069469 Li Apr 2003 A1
20030078468 Skiba et al. Apr 2003 A1
20030100954 Schuldt Hempe et al. May 2003 A1
20030130670 Anderson et al. Jul 2003 A1
20030149440 Kammerer et al. Aug 2003 A1
20030171644 Anderson et al. Sep 2003 A1
20030176762 Kammerer Sep 2003 A1
20030176875 Anderson et al. Sep 2003 A1
20030191360 Browning Oct 2003 A1
20030199732 Suslian et al. Oct 2003 A1
20030212305 Anderson et al. Nov 2003 A1
20030220538 Jacquetin Nov 2003 A1
20040029478 Planck et al. Feb 2004 A1
20040034373 Schuldt Hempe et al. Feb 2004 A1
20040039453 Anderson et al. Feb 2004 A1
20040059356 Gingras Mar 2004 A1
20040097974 De Leval May 2004 A1
20040106847 Benderev Jun 2004 A1
20040144395 Evans et al. Jul 2004 A1
20040172048 Browning Sep 2004 A1
20040231678 Fierro Nov 2004 A1
20040243166 Odermatt et al. Dec 2004 A1
20040249240 Goldmann et al. Dec 2004 A1
20040249373 Gronemeyer et al. Dec 2004 A1
20040249397 Delorme et al. Dec 2004 A1
20040249473 Delorme et al. Dec 2004 A1
20050000524 Cancel et al. Jan 2005 A1
20050004576 Benderev Jan 2005 A1
20050065486 Fattman Mar 2005 A1
20050080317 Merade Apr 2005 A1
20050107805 Bouffier et al. May 2005 A1
20050131274 Suslian et al. Jun 2005 A1
20050240076 Neisz et al. Oct 2005 A1
20050277806 Cristalli Dec 2005 A1
20050278037 Delorme et al. Dec 2005 A1
20050283040 Greenhalgh Dec 2005 A1
20060015069 Evans et al. Jan 2006 A1
20060025649 Smith et al. Feb 2006 A1
20060025783 Smith et al. Feb 2006 A1
20060041185 Browning Feb 2006 A1
20060058578 Browning Mar 2006 A1
20060089524 Chu Apr 2006 A1
20060089525 Mamo et al. Apr 2006 A1
20060130848 Carey Jun 2006 A1
20060205995 Browning Sep 2006 A1
20060264698 Kondonis et al. Nov 2006 A1
20070015953 MacLean Jan 2007 A1
20070020311 Browning Jan 2007 A1
20070032695 Weiser Feb 2007 A1
20070032881 Browning Feb 2007 A1
20070059199 Labuschagne Mar 2007 A1
20070149555 Kase et al. Jun 2007 A1
20070219606 Moreci et al. Sep 2007 A1
20080021263 Escude et al. Jan 2008 A1
20080161837 Toso et al. Jul 2008 A1
20080161850 Weisenburgh et al. Jul 2008 A1
20080167518 Burton et al. Jul 2008 A1
20080196729 Browning Aug 2008 A1
20080200751 Browning Aug 2008 A1
20080281148 Evans et al. Nov 2008 A1
20090123522 Browning May 2009 A1
20090137862 Evans et al. May 2009 A1
20090171377 Intoccia et al. Jul 2009 A1
20090221868 Evans Sep 2009 A1
20090287229 Ogdahl Nov 2009 A1
20100022822 Walshe Jan 2010 A1
20100056856 Suslian et al. Mar 2010 A1
20100063351 Witzmann et al. Mar 2010 A1
20100113869 Goldman May 2010 A1
20100130814 Dubernard May 2010 A1
20100198002 O'Donnell Aug 2010 A1
20100222794 Browning Sep 2010 A1
20100222974 Nakamura et al. Sep 2010 A1
20100256442 Ogdahl et al. Oct 2010 A1
20100274074 Khamis et al. Oct 2010 A1
20100280308 Browning Nov 2010 A1
20100298630 Wignall Nov 2010 A1
20110021868 Browning Jan 2011 A1
20110034759 Ogdahl et al. Feb 2011 A1
20110105833 Gozzi et al. May 2011 A1
20110124954 Ogdahl et al. May 2011 A1
20110124956 Mujwid et al. May 2011 A1
20110201872 Browning Aug 2011 A1
20110230705 Browning Sep 2011 A1
20110230708 Browning Sep 2011 A1
20110230709 Browning Sep 2011 A1
20110237865 Browning Sep 2011 A1
20110237866 Browning Sep 2011 A1
20110237867 Browning Sep 2011 A1
20110237868 Browning Sep 2011 A1
20110237869 Browning Sep 2011 A1
20110237870 Browning Sep 2011 A1
20110237873 Browning Sep 2011 A1
20110237874 Browning Sep 2011 A1
20110237875 Browning Sep 2011 A1
20110237876 Browning Sep 2011 A1
20110237877 Browning Sep 2011 A1
20110237878 Browning Sep 2011 A1
20110237879 Browning Sep 2011 A1
20110238095 Browning Sep 2011 A1
20110245594 Browning Oct 2011 A1
20110282136 Browning Nov 2011 A1
20110319705 Browning Dec 2011 A1
20110319706 Browning Dec 2011 A1
20120083649 Suslian et al. Apr 2012 A1
20120083651 Browning Apr 2012 A1
20120116154 Evans et al. May 2012 A1
20120143000 Browning Jun 2012 A1
20120149977 Browning Jun 2012 A1
20120199133 Browning Aug 2012 A1
20130281775 Browning Oct 2013 A1
20130289340 Browning Oct 2013 A1
20130289341 Browning Oct 2013 A1
20140039244 Browning Feb 2014 A1
20140039247 Browning Feb 2014 A1
20140039248 Browning Feb 2014 A1
20140051917 Browning Feb 2014 A1
20140303429 Evans et al. Oct 2014 A1
20140303430 Evans et al. Oct 2014 A1
Foreign Referenced Citations (148)
Number Date Country
2592617 Feb 2004 CA
2305815 Aug 1974 DE
4220283 Dec 1993 DE
4304353 Apr 1994 DE
10019604 Jun 2002 DE
10211360 Oct 2003 DE
0009072 Apr 1980 EP
0024781 Aug 1984 EP
0024780 Oct 1984 EP
0248544 Apr 1991 EP
0437481 Jul 1991 EP
0139286 Aug 1991 EP
0470308 Feb 1992 EP
0556313 Aug 1993 EP
0557964 Sep 1993 EP
0632999 Jan 1995 EP
0650703 May 1995 EP
0706778 Apr 1996 EP
0740925 Nov 1996 EP
0745351 Dec 1996 EP
0778749 Jun 1997 EP
0854691 Jul 1998 EP
0983033 Mar 2000 EP
1093758 Apr 2001 EP
0719527 Aug 2001 EP
1151722 Nov 2001 EP
1159921 Dec 2001 EP
0643945 Mar 2002 EP
1342454 Sep 2003 EP
1545285 Jun 2005 EP
1060714 Aug 2006 EP
1274370 Sep 2006 EP
1296614 Sep 2006 EP
1353598 Oct 2007 EP
0797962 Sep 2009 EP
1274370 Oct 1961 FR
2712177 May 1995 FR
2732582 Oct 1997 FR
2735015 Feb 1998 FR
2811218 Nov 2000 FR
2787990 Apr 2001 FR
0378288 Aug 1932 GB
2353220 Feb 2001 GB
4452180 Nov 2005 JP
2187251 Aug 2002 RU
2196518 Jan 2003 RU
1225547 Apr 1986 SU
1342486 Oct 1987 SU
1475607 Apr 1989 SU
1990003766 Apr 1990 WO
1991000714 Jan 1991 WO
1993017635 Sep 1993 WO
1993019678 Oct 1993 WO
1995033454 Dec 1995 WO
1996003091 Feb 1996 WO
1996006567 Mar 1996 WO
199706567 Feb 1997 WO
1997013465 Apr 1997 WO
1997022310 Jun 1997 WO
1997043982 Nov 1997 WO
1998019606 May 1998 WO
1998035606 Aug 1998 WO
1998035616 Aug 1998 WO
1998035632 Aug 1998 WO
1998057590 Dec 1998 WO
1999016381 Apr 1999 WO
1999052450 Oct 1999 WO
1999059477 Nov 1999 WO
2000007520 Feb 2000 WO
2000013601 Mar 2000 WO
2000015141 Mar 2000 WO
2000018319 Apr 2000 WO
2000018325 Apr 2000 WO
2000027304 May 2000 WO
2000038784 Jul 2000 WO
2000057812 Oct 2000 WO
2000064370 Nov 2000 WO
2000066030 Nov 2000 WO
2000074594 Dec 2000 WO
2000074613 Dec 2000 WO
2000074633 Dec 2000 WO
2001006951 Feb 2001 WO
2001026581 Apr 2001 WO
2001039670 Jun 2001 WO
2001045589 Jun 2001 WO
2001052729 Jul 2001 WO
2001052750 Jul 2001 WO
2001056499 Aug 2001 WO
2001080773 Nov 2001 WO
2002002031 Jan 2002 WO
2002019946 Mar 2002 WO
2002026108 Apr 2002 WO
2002028312 Apr 2002 WO
2002028315 Apr 2002 WO
2002030293 Apr 2002 WO
2002032284 Apr 2002 WO
2002032346 Apr 2002 WO
2002034124 May 2002 WO
2002039890 May 2002 WO
2002039914 May 2002 WO
2002058562 Aug 2002 WO
2002058563 Aug 2002 WO
2002058564 Aug 2002 WO
2002058565 Aug 2002 WO
2002060371 Aug 2002 WO
2002062237 Aug 2002 WO
2002065921 Aug 2002 WO
2002065922 Aug 2002 WO
2002065923 Aug 2002 WO
2002065944 Aug 2002 WO
2002069781 Sep 2002 WO
2002071931 Sep 2002 WO
2002071953 Sep 2002 WO
2002078548 Oct 2002 WO
2002078552 Oct 2002 WO
2002078568 Oct 2002 WO
2002078571 Oct 2002 WO
2002098322 Dec 2002 WO
2002098340 Dec 2002 WO
2003002027 Jan 2003 WO
2003013369 Feb 2003 WO
2003013392 Feb 2003 WO
2003057074 Jul 2003 WO
2003068107 Aug 2003 WO
2003075792 Sep 2003 WO
2003022260 Oct 2003 WO
2003086205 Oct 2003 WO
2003092546 Nov 2003 WO
2003094781 Nov 2003 WO
2003096928 Nov 2003 WO
2003096930 Nov 2003 WO
2004002370 Jan 2004 WO
2004002379 Jan 2004 WO
2004004600 Jan 2004 WO
2004012626 Feb 2004 WO
2004016196 Feb 2004 WO
2004019786 Mar 2004 WO
2004012579 May 2004 WO
2004098461 Nov 2004 WO
2005018494 Mar 2005 WO
2005112842 Dec 2005 WO
2006015031 Feb 2006 WO
2006015042 Feb 2006 WO
2006136625 Dec 2006 WO
2007059199 May 2007 WO
2007149555 Dec 2007 WO
2008007086 Jan 2008 WO
2008018494 Feb 2008 WO
Non-Patent Literature Citations (224)
Entry
Ulmsten et al., “The unstable female urethra,” Am. J. Obstet. Gynecol., 1982, 144:93-97.
Ulmsten, “Female Urinary Incontinence—A Symptom, Not a Urodynamic Disease. Some Theoretical and Practical Aspects on the Diagnosis and Treatment of Female Urinary Incontinence,” Int. Urogynecol. J., 1995, 6:2-3.
Ulstem et al., “A Multicenter Study of Tension-Free Vaginal Tape (TVT) for Surgical Treatment of Stress Urinary Incontinence,” Int. Urogynecol. J., 1998, 9:210-213.
U.S. Appl. No. 13/149,994, filed Jun. 1, 2011.
U.S. Appl. No. 60/327,160, filed Oct. 4, 2001.
U.S. Appl. No. 10/106,086, filed Mar. 25, 2002.
U.S. Appl. No. 11/199,061, filed Aug. 8, 2005.
U.S. Appl. No. 60/279,794, filed Mar. 29, 2001.
U.S. Appl. No. 60/302,929, filed Jul. 3, 2001.
U.S. Appl. No. 60/307,836, filed Jul. 25, 2001.
U.S. Appl. No. 60/322,309, filed Sep. 14, 2001.
U.S. Appl. No. 60/362,806, filed Mar. 7, 2002.
U.S. Appl. No. 60/380,797, filed May 14, 2002.
U.S. Appl. No. 60/393,969, filed Jul. 5, 2002.
U.S. Appl. No. 60/402,007, filed Aug. 8, 2002.
U.S. Appl. No. 60/414,865, filed Sep. 30, 2002.
Webster and Kreder, “Voiding Dysfunction Following Cystourethropexy: Its Evaluation and Management,” J. Urol., 1990, 144:670-673.
Weidemann, Small Intestinal Submucosa for Pubourethral Sling Suspension for the Treatment of Stress Incontinence: First Histopathological Results in Humans, Jul. 2004.
Winter, “Peripubic Urethropexy for Urinary Stress Incontinence in Women,” Urology, 1982, 20(4):408-411.
Woodside and Borden, “Suprapubic Endoscopic Vesical Neck Suspension for the Management of Urinary Incontinence in Myelodysplastic Girls,” J. Urol., 1986, 135:97-99.
Written Opinion for PCT/GB2009/050174, dated Jun. 24, 2009.
Written Opionion issued in PCT/GB2007/002589, dated Jan. 22, 2008, 5 pages.
Zacharin and Hamilton, “Pulsion Enterocele: Long-Term Results of an Abdominoperineal Technique,” Obstet. Gynecol., 1980, 55(2):141-148.
Zacharin, “The suspensory mechanism of the female urethra,” J. Anat., 1963, 97(3):423-427.
Abdel-fattah, Mohamed et al. Evaluation of transobturator tapes (E-TOT) study: randomised prospective single-blinded study comparing inside-out vs. outside-in transobturator tapes in management of urodynamic stress incontinence: Short term outcomes, European Journal of Obstetrics & Gynecology and Reproductive Biology (2009).
Accelerated Examination Search for Surgical Implant—Abutment System and Method, Mar. 31, 2011, 10 pages.
Accelerated Examination Search for Surgical Implant—Adjustable, Mar. 4, 2011, 10 pages.
Accelerated Examination Search for Surgical Implant—Fiber Entanglement, Mar. 4, 2011, 8 pages.
Accelerated Examination Search for Surgical Implant—Introducer, Mar. 31, 2011, 12 pages.
Adjustable Mini-Sling, Just-Swing SVS “Secured Vaginal Sling”, Polypropylene, Mar. 2010.
Ajust Adjustable Single-Incision Sling, http://www.bardnordic.com, Mar. 1, 2011.
Ajust(TM) Adjustable Single-Incision Sling, retrieved from www.bardnordic.com/main/product.asp?sectionTypeId=2&section, accessed Mar. 1, 2011, 1 page.
Aldridge, “Transplantation of Fascia for Relief of Urinary Stress Incontinence,” Am. J. Obstet. Gynecol., 1942, 44:398-411.
Amended Answer and Counterclaim (Mar. 30, 2004) American Medical Systems, Inc. v. Mentor Corporation, Civ. No. 03-5759.
American Heritage Dictionary, 2nd College Edition (1991).
AMS's Reply to Mentor's Counterclaim (Apr. 5, 2004) American Medical Systems, Inc. v. Mentor Corporation, Civ. No. 03-CV-5759.
Answer and Counterclaim (Mar. 15, 2004) American Medical Systems, Inc. v. Mentor Corporation, Civ. No. 03-5759.
Answer and Counterclaim of American Medical Systems, Inc. (Mar. 11, 2004) Mentor Corporation v. American Medical Systems, Inc., Civ. Case No. 04-1000 DWF/SRN.
Araki et al., “The Loop-Loosening Procedure for Urination Difficulties After Stamey Suspension of the Vesical Neck,” J. Urol., 1990, 144:319-323.
Asmussen and Ulmsten, “Simultaneous Urethro-Cystometry with a New Technique,” Scand. J. Urol. Nephrol., 1976, 10:7-11.
Beck and McCormick, “Treatment of Urinary Stress Incontinence with Anterior Colporrhaphy,” Obstetrics and Gynecology, 1982, 59(3):271-274.
Benderev, “A Modified Percutaneous Outpatient Bladder Neck Suspension System,” J. Urol., 1994, 152:2316-2320.
Benderev, “Anchor Fixation and Other Modifications of Endoscopic Bladder Neck Suspension,” Urology, 1992, 40(5):409-418.
Bergman and Elia, “Three surgical procedures for genuine stress incontinence: Five-year follow-up of a prospective randomized study,” Am. J. Obstet. Gynecol., 1995, 173:66-71.
BioArc SP Sling Kit, www.AmericanMedicalSystems.com, 2006.
BioArc(R) SP Sling Kit: 12 Step Procedure, American Medical Systems Inc. Online Brochure 2006, 2 pages.
Blaivas and Jacobs, “Pubovaginal Fascial Sling for the Treatment of Complicated Stress Urinary Incontinence,” J. Urol., 1991, 145:1214-1218.
Blaivas and Salinas, “Type III Stress Urinary Incontinence: Importance of Proper Diagnosis and Treatment,” American College of Surgeons Surgical Forum, 1984, 70.sup.th Annual Clinical Congress, San Francisco, CA, vol. XXXV, pp. 473-474.
Botros, Cystocele and Rectocele Repair: More Success With Mesh? Jun. 2006.
Bryans, “Marlex gauze hammock sling operation with Cooper's ligament attachment in the management of recurrent urinary stress incontinence,” Am. J. Obstet. Gynecol., 1979, 133(3):292-294.
Burch, “Urethrovaginal fixation to Cooper's ligament for correction of stress incontinence, cystocele, and prolapse,” Am. J. Obstet. Gynecol., 1961, 81(2):281-290.
Canepa, G. et al., “Horseshoe-shaped Marlex mesh for the treatment of pelvic floor prolapse,” European Urology (Jan. 2001) 39 (Supl 2): 23-27.
Certified priority document for GB Application No. 0025068.8, filed Oct. 12, 2000, 38 pages.
Certified priority document for GB Application No. 0208359.0, filed Apr. 11, 2002, 50 pages.
Certified priority document for GB Application No. 0411360.1, filed May 21, 2004, 31 pages.
Chen, Biologic Grafts and Synthetic Meshes in Pelvic Reconstructive Surgery, Jun. 2007.
Choe and Staskin, “Gore-Tex Patch Sling: 7 Years Later,” Urology, 1999, 54:641-646.
Chopra et al., “Technique of Rectangular Fascial Sling,” Female Urology, 1996, Raz (ed.), W.B. Saunders Company, Chapter 34, pp. 392-394.
Churchill's Medical Dictionary (1989).
Complaint and Jury Demand (Feb. 8, 2010), Coloplast A/S v. Mpathy Medical Devices, Inc., Court File No. CV10-206.
Complaint for Declaratory Judgment (Oct. 28, 2003) American Medical Systems, Inc. v. Mentor Corporation.
Complaint for Patent Infringement (Feb. 20, 2004) Mentor Corporation v. American Medical Systems, Inc.
Complaint for Patent Infringement and Exhibits (Feb. 8, 2010) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV10-227 BHS.
Cook, Urogynecology, Product Technical Datasheet and Order form, 1996.
D. Elliott Declaration and Attachment 1 (Jan. 5, 2011) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV 10-227 BHS.
Dargent, D. et al., Pose d'un ruban sous uretral oblique par voie obturatrice dans le traitement de L'incontinence urinary feminine [English “Insertion of a transobturator oblique suburethral sling in the treatment of female urinary incontinence”], Gynecol. Obstet. Ferril. 14, pp. 576-582 (2002) [including English translation at the beginning of document].
Das and Palmer, “Laparoscopic Colpo-Suspension,” J. Urol., 1995, 154:1119-1121.
De Leval, J., “Novel Surgical Technique for the Treatment of Female Stress Urinary Continence: Transobturator Vaginal Tape Inside-Out,” European Urology, 2003, 44:724-730.
DeBord, James R., (1998), “The Historical Development of Prosthetics in Hernia Surgery,” Surgical Clinics of North America, 78(6): 973-1006.
Declaration of Dr. George D. Webster in Support of Generic Medical Devices, Inc.'s Briefing on Claim Construction and Exhibits for Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV 10-227 BHS, signed Jan. 5, 2011.
Declaration of Jeya Paul and Attachment 1 (Jan. 10, 2011) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV 10-227 BHS.
Declaration of Marc Belloli in Support of GMD's Opening Claim Construction Brief and Exhibits A-J (Jan. 10, 2011) Coloplast A/S v. Generic Medical Devices, Inc., Court File No. CV 10-227 BHS.
Decter, “Use of the Fascial Sling for Neurogenic Incontinence: Lessons Learned,” J. Urol., 1993, 150:683-686.
Delmore, E. et al., La bandelette trans-obturatrice: Un procede mini-invasif pour traiter l'incontinence urinaire d'effort de la femme, Progres en Urologie, vol. 11, pp. 1306-1313 (2001) [including English translation at the beginning of document].
Kovac, R. S. Follow-Up of the Pubic Bone Suburethral Stabilization Sling for Recurrent Urinary Incontinence (Kovac Procedure). Journal of Pelvic Surgery, 5(3): 156-160, 1999.
Kovac, R., et. al. Pubic Bone Suburethral Stablization Sling for Recurrent Urinary Incontinence. Obstetrics & Genecology: Instruments & Methods, 89(4): 624-627, Apr. 1997.
Lazarevski, M.B., Suburethral Duplication of the Vaginal Wall—An Original Operation for Urinary Stress Incontinence in Women, 6 Int'l Urogynecol. J. 73-79 (1995).
Leach et al., “Female Stress Urinary Incontinence Clinical Guidelines Panel Summary Report on Surgical Management of Female Stress Urinary Incontinence,” J. Urol., 1997, 158:875-880.
Leach, “Bone Fixation Technique for Transvaginal Needle Suspension,” Urology, 1988, 31(5):388-390.
Lichtenstein et al., “The Tension-Free Hernioplasty,” Am. J. Surgery, 1989, 157:188-193.
Lipton, S. and Estrin, J., “A Biomechanical Study of the Aponeurotic Iguinal Hernia Repair,” Journal of the American College of Surgeons, Jun. 1994, vol. 178, pp. 595-599.
Loughlin et al., “Review of an 8-Year Experience with Modifications of Endoscopic Suspension of the Bladder Neck for Female Stress Urinary Incontinence,” J. Urol., 1990, 143:44-45.
Maher, Surgical Management of Anterior Vaginal Wall Prolapse: An Evidence Based Literature Review, 2006.
Mahoney and Whelan, “Use of Obturator Foramen in Iliofemoral Artery Grafting: Case Reports,” Annals of Surgery, 1966, 163(2):215-220.
Marshall et al., “The Correction of Stress Incontinence by Simple Vesicourethral Suspension,” J. Urol., 2002, 168:1326-1331.
McGuire and Gormley, “Abdominal Fascial Slings,” Female Urology, 1996, Raz (ed.), W.B. Saunders Company, Chapter 31, pp. 369-375.
McGuire and Lytton, “Pubovaginal Sling Procedure for Stress Incontinence,” J. Urol., 1978, 119:82-84.
McGuire et al., “Experience with Pubovaginal Slings for Urinary Incontinence at the University of Michigan,” J. Urol., 1987, 138:525-526.
McGuire, “Abdominal Procedures for Stress Incontinence,” Urologic Clinics of North America, 1985, 12(2):285-290.
McIndoe et al., “The Aldridge Sling Procedure in the Treatment of Urinary Stress Incontinence,” Aust. NZ J. Obstet. Gynaecol., 1987, 27:238-239.
McKiel, Jr. et al., “Marshall-Marchetti Procedure: Modification,” J. Urol., 1966, 96:737-739.
Migliari, R. et al., “Tension-Free Vaginal Mesh Repair for Anterior Vaginal Wall Prolapse,” European Urology (2000) 38(2): 151-155.
Miklos, Mini Sling Incontinence Treatment—Vagina Plastic Surgery, http://www.miklosandmoore.com/mini_sling.php, Feb. 28, 2011.
MiniArc Single-Incision Sling http://www.americanmedicalsystems.com Mar. 4, 2011.
Moir, “The Gauze-Hammock Operation,” The Journal of Obstetrics and Gynaecology of the British Commonwealth, 1968, 75(1):1-9.
Monseur, J., Anatomie Chirurgicale: Les Ligaments Du Perinee Feminin, Sep. 4, 2008.
Moore et al. “Single-Center Retrospective Study of the Technique, Safety, and 12 Month Efficacy or the MiniArc™ Single Incision Sling: A New Minimally Invasive Procedure for Treatment of Female SUI” [Online] 2009, 18, pp. 175-181.
Morgan et al., “The Marlex sling operation for the treatment of recurrent stress urinary incontinence: A 16-year review,” Am. J. Obstet. Gynecol., 1985, 151:224-226.
Morgan, “A sling operation, using Marlex polypropylene mesh, for treatment of recurrent stress incontinence,” Am. J. Obstet. Gynecol., 1970, 106(3):369-376.
Narik and Palmrich, “A simplified sling operation suitable for routine use,” Am. J. Obstet. Gynecol., 1962, 84:400-405.
Nichols, “The Mersilene Mesh Gauze-Hammock for Severe Urinary Stress Incontinence,” Obstet. Gynecol., 1973, 41(1):88-93.
Nicita, Giulio, (1998), “A New Operation for Genitourinary Prolapse,” The Journal of Urology, 160:741-745.
Nickel et al., “Evaluation of a Transpelvic Sling Procedure With and Without Colpolsuspension for Treatment of Female Dogs With Refractory Urethral Sphincter Mechanism Incompetence,” Veterinary Surgery, 1998, 27:94-104.
Norris et al., “Use of Synthetic Material in Sling Surgery: A Minimally Invasive Approach,” J. Endocrinology, 1996, 10(3):227-230.
Novak, “Abdonomovaginal Techniques,” Gynecological Surgical Technique, 1977, Piccin Editore, Padua, 5 pages.
O'Donnell, “Combined Raz Urethral Suspension and McGuire Pubovaginal Sling for Treatment of Complicated Stress Urinary Incontinence,” J. Arkansas Medical Society, 1992, 88(8):389.
Order dismissing cases (Sep. 16, 2004) Civ. No. 03-5759 and Civ. No. 04-1000.
Parker, MC and Phillips, RK, “Repair of rectocoele using Marlex mesh,” Ann R Coll Surg Engl (May 1993) 75(3):193-194.
Parra and Shaker, “Experience with a Simplified Technique for the Treatment of Female Stress Urinary Incontinence,” British Journal of Urology, 1990, 66:615-617.
Pelosi II and Pelosi III, “New transobturator sling reduces risk of injury,” OBG Management, 2003, pp. 17-37.
Pelosi III and Pelosi. Pubic Bone Suburethral Stabilization Sling: Laparoscopic Assessment of a Transvaginal Operation for the Treatment of Stress Urinary Incontinence. Journal of Laparoendoscopic & Advanced Surgical Techniques: 9(1): 45-50, 1999.
Penson and Raz, “Why Anti-incontinence Surgery Succeeds or Fails,” Female Urology, 1996, Raz (ed.), W.B. Saunders Company, Chapter 41, pp. 435-442.
Pereyra et al., “Pubourethral Supports in Perspective: Modified Pereyra Procedure for Urinary Incontinence,” Obstet Gynecol., 1982, 59:643-648.
Petros and Konsky, “Anchoring the midurethra restores bladder-neck anatomy and continence,” The Lancet, 1999, 354:997-998.
Petros and Ulmsten, “An analysis of rapid pad testing and the history for the diagnosis of stress incontinence,” Acta Obstet. Gynecol. Scand., 1992, 71:529-536.
Petros and Ulmsten, “An Anatomical Basis for Success and Failure of Female Incontinence Surgery,” Scand. J. Urol. Nephrol., 1993, (Suppl. 153):55-60.
Petros and Ulmsten, “Bladder Instability in Women: A Premature Activation of the Micturition Reflex,” Neurourology and Urodynamics, 1993, 12:235-239.
Petros and Ulmsten, “Cough Transmission Ratio: An Indicator of Suburethral Vaginal Wall Tension Rather than Urethral Closure?” Acta Obstet. Gynecol. Scand., 1990, 69(Suppl. 153):37-38.
Petros and Ulmsten, “Cure of Stress Incontinence by Repair of External Anal Sphincter,” Acta. Obstet. Gynecol Scand., 1990, 69(Suppl. 153):75.
Petros and Ulmsten, “Cure of Urge Incontinence by the Combined Intravaginal Sling and Tuck Operation,” Acta Obstet. Gynecol. Scand., 1990, 69(Suppl. 153)61-62.
Petros and Ulmsten, “Further Development of the Intravaginal Slingplasty Procedure—IVS III—(with midline “tuck”),” Scand. J. Urol. Nephrol., Suppl. 153 An Integral Theory and its Method for the Diagnosis and Management of Female Urinary Incontinence: 69-71 , 1993.
Petros and Ulmsten, “Non Stress Non Urge Female Urinary Incontinence—Diagnosis and Cure: A Preliminary Report,” Acta Obstet. Gynecol. Scand., 1990, 69(Suppl. 153):69-70.
Petros and Ulmsten, “Part I: Theoretical, Morphological, Radiographical Correlations and Clinical Perspective,” Scand. J. Urol. Nephrol., 1993, Suppl. 153:5-28.
Petros and Ulmsten, “Part II:The Biomechanics of Vaginal Tissue and supporting Ligaments with Special Relevance to the Pathogenesis of Female Urinary Incontinence,” Scand. J. Urol. Nephrol., 1993, Suppl. 153:29-40.
DeTayrac, et al. Prolapse repair by vaginal route using . . . Int. Urogynecol. J. (published online May 13, 2006).
Dwyer, Transvaginal repair of anterior and posterior compartment prolapse with Atrium polypropylene mesh, BJOG: An International Journal of Obstetrics & Gynaecology, Aug. 2004.
Enzelsberger et al., “Urodynamic and Radiologic Parameters Before and After Loop Surgery for Recurrent Urinary Stress Incontinence,” Acta Obstet. Gynecol. Scand., 1990, 69:51-54.
Eriksen et al., “Long-Term Effectiveness of the Burch Colposuspension in Female Urinary Stress Incontinence,” Acta Obstet. Gynecol. Scand., 1990, 69:45-50.
Falconer et al., “Clinical Outcome and Changes in Connective Tissue Metabolism After Intravaginal Slingplasty in Stress Incontinent Women,” Int. Urogynecol. J., 1996, 7:133-137.
Falconer et al., “Influence of Different Sling Materials on Connective Tissue Metabolism in Stress Urinary Incontinent Women,” Int. Urogynecol. J., 2001, (Suppl. 2):S19-S23.
Generic Medical Devices, Inc 's Answer to Complaint and Counterclaims (Mar. 1, 2010) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV10-227 BHS.
Generic Medical Devices, Inc.'s Non, Infringement and Invalidity Contentions and Accompanying Document Production (Aug. 9, 2010) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV-10-227 BHS.
Generic Medical Devices, Inc.'s Opening Claim Construction Brief (Jan. 10, 2011) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV10-227 BHS.
Gilja et al., “A Modified Raz Bladder Neck Suspension Operation (Transvaginal Burch),” J. Urol., 1995, 153:1455-1457.
Gittes and Loughlin, “No-Incision Pubovaginal Suspension for Stress Incontinence,” J. Urol., 1987, 138:568-570.
Gruss, “The Obturator Bypass. Indications. Techniques. Outcomes,” Chirurgie, 1971, 97:220-226.
Guida and Moore, “The Surgeon At Work. Obturator Bypass Technique,” Surgery, Gynecology & Obstetrics, 1969, pp. 1307-1315.
Handa et al., “Banked Human Fascia Lata for the Suburethral Sling Procedure: A Preliminary Report,” Obstet. Gynecol., 1996, 88:1045-1049.
Hardiman, et al. Cystocele repair using polypropylene mesh. Br. J. Obstet. Gynaecol. 107: 825-26 (2000).
Henriksson and Ulmsten, “A urodynamic evaluation of the effects of abdominal urethrocystopexy and vaginal sling urethroplasty in women with stress incontinence,” Am. J. Obstet. Gynecol., 1978, 131:77-82.
Hodgkinson and Kelly, “Urinary Stress Incontinence in the Female. III. Round-ligament technique for retropubic suspension of the urethra,” Obstet. Gynecol., 1957, 10:493-499.
Hohenfellner and Petri, “Sling Procedures,” Surgery of Female Incontinence, 2nd edition, SpringerVeriag, pp. 105-113, 1986.
Holschneider et al., “The Modified Pereyra Procedure in Recurrent Stress Urinary Incontinence: A 15-Year Review,” Obstet. Gynecol., 1994, 83:573-578.
Horbach et al., “A Suburethral Sling Procedure with Polytetrafluoroethylene for the Treatment of Genuine Stress Incontinence in Patients with Low Urethral Closure Pressure,” Obstet. Gynecol., 1988, 71:648-652.
Horbach, “Suburethral Sling Procedures,” Urogynecology and Urodynamics—Theory and Practice, 1996, Williams & Wilkins, pp. 569-579.
Ingelman-Sundberg and Ulmsten, “Surgical Treatment of Female Urinary Stress Incontinence,” Contr. Gynec. Obstet., 1983, 10:51-69.
International Preliminary Examination Report issued in PCT/GB01/04554, completed Nov. 22, 2002, 6 pages.
International Preliminary Examination Report issued in PCT/GB2002/001234, completed Jul. 1, 2003, 18 pages.
International Search Report and Written Opinion issued in PCT/GB2004/001390, dated Sep. 3, 2004, 12 pages.
International Search Report and Written Opinion issued in PCT/US03/24212, dated May 28, 2004, 11 pages.
International Search Report for PCT/GB2009/050174, dated Jun. 24, 2009.
International Search Report issued in PCT/GB01/04554, dated Jan. 29, 2002, 3 pages.
International Search Report issued in PCT/GB2002/01234 dated Jun. 5, 2002, 3 pages.
International Search Report issued in PCT/GB2007/002589, dated Jan. 22, 2008, 5 pages.
Jacquetin, Bernard, “2. Utilisation du “TVT” dans la chirurgie de l'incontinence urinaire feminine”, J. Gynecol. Obstet. Biol. Reprod. 29: 242-47 (2000).
Jeffcoate, “The Results of the Aldridge Sling Operation for Stress Incontinence,” The Journal of Obstetrics and Gynaecology of the British Empire, 1956, 63:36-39.
Jeter, “The Social Impact of Urinary Incontinence,” Female Urology, Raz (ed.), W. B. Saunders Company, 1996, Chapter 7, pp. 80-86.
Joint Claim Construction and Prehearing Statement Pursuant to Local Patent Rule 132 and Appendix A (Nov. 15, 2010) Coioplast A/S, v. Generic Medical Devices, Inc., Court File No. CV10-227 BHS.
Just-Swing(R) Adjustable mine-sling, Textile Hi-Tec Online Brochure 2010, 4 pages.
Karram and Bhatia, “Patch Procedure: Modified Transvaginal Fascia Lata Sling for Recurrent or Severe Stress Urinary Incontinence,” Obstet Gynecol., 1990, 75:461-463.
Kennelly et al. “Prospective Evaluation of a Single Incision Sling for Stress Urinary Incontinence” The Journal of Urology [Online] 2010, 184, pp. 604-609.
Kerdiles et al., “Bypass via the Obturator Foramen in Reconstructive Arterial Surgery of the Lower Extremities,” Ann. Chir. Thorac. Cardio-Vasc., 1974, 13(4):335-341.
Kerr and Staskin, “The Use of Artificial Material for Sling Surgery in the Treatment of Female Stress Urinary Incontinence,” Female Urology, 1996, Raz (ed.), W.B. Saunders Company, Chapter 33, pp. 382-391.
Kersey, “The gauze hammock sling operation in the treatment of stress incontinence,” Br. J. Obstet. Gynecol., 1983, 90:945-949.
Klinge et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair,” Journal of Biomedical Material Research, Jan. 24, 2002, pp. 129-137.
Klinge, U. et al., “Influence of polyglactin-coating on functional and morphological parameters of polypropylene-mesh modifications for abnormal wall repair,” Biomaterials 20 (1999), pp. 613-623.
Klinge, U. et al., “Modified Mesh for Hernia Repair that is Adapted to the Physiology of the Abdominal Wall,” Eur J Surg 164:951-960 (1998).
Klinge, U. et al., “Pathophysiology of the abdominal wall,” Der Chirurg, (1996),67: 229-233.
Klosterhalfen, B, et al., “Functional and morphological evaluation of different polypropylene-mesh modifications for abdominal wall repair,” Biomaterials 19:2235-2246 (1998).
Klosterhalfen, B. et al., “Morphological correlation of the functional mechanics of the abdominal wall after mesh implantation,” Langenbecks Arch Chir 382:87-94 (1997).
Klutke et al., “The Anatomy of Stress Incontinence: Magnetic Resonance Imaging of the Female Bladder Neck and Urethra,” J. Urol., 1990, 143:563-566.
Klutke et al., “Transvaginal Bladder Neck Suspension to Cooper's Ligament: A Modified Pereyra Procedure,” Obstet. Gynecol., 1996, 88:294-297.
Korda et al., “Experience with Silastic Slings for Female Urinary Incontinence,” Aust. NZ J. Obstet. Gynaecol., 1989, 29:150-154.
Kovac and Cruikshank. Pubic bone suburethral stabilization sling: a long-term cure for SUI? Contemporary OB/GYN: Surgical Techniques, 43(2):52-76, 1998.
Petros and Ulmsten, “Part III: Surgical Principles Deriving from the Theory,” Scand. J. Urol. Nephrol., 1993, Suppl. 153:41-52.
Petros and Ulmsten, “Part IV: Surgical Applications of the Theory—Development of the Intravaginal Sling Plasty (IVS) Procedure,” Scand. J. Urol. Nephrol., 1993, Suppl. 153:53-54.
Petros and Ulmsten, “Pinch Test for Diagnosis of Stress Urinary Incontinence,” Acta Obstet. Gynecol. Scand., 1990, 69(Suppl.153):33-35.
Petros and Ulmsten. An Integral Theory of Female Urinary Incontinence. Acta Obstet. Gynecol. Scand., 1990, 69 (Suppl.153):7-31.
Petros and Ulmsten. Pregnancy Effects on the Intravaginal Sling Operation. Acta Obstet. Gynecol. Scand., 69(Suppl. 153 An Integral Theory of Female Urinary Incontinence) :77-78, 1990.
Petros and Ulmsten. The Combined Intravaginal Sling and Tuck Operation. An Ambulatory Procedure for Cure of Stress and Urge Incontinence. Acta Obstet. Gynecol. Scand., 69(Suppl. 153 An Integral Theory of Female Urinary Incontinence): 53-59, 1990.
Petros and Ulmsten. The Development of the Intravaginal Slingplasty Procedure: IVS II—(with bilateral “tucks”). Scand. J. Urol. Nephrol., Suppl. 153 An Integral Theory and its Method for the Diagnosis and Management of Female Urinary Incontinence: 61-67, 1993.
Petros and Ulmsten. The Free Graft Procedure for Cure of the Tethered Vagina Syndrome. Scand. J. Urol. Nephrol., Suppl. 153: 85-87, 1997.
Petros and Ulmsten. The Further Development of the Intravaginal Slingplasty Procedure: IVS IV—(with “double-breasted” unattached vaginal flap repair and “free” vaginal tapes). Scand. J. Urol. Nephrol., Suppl. 153 An Integral Theory and its Method for the Diagnosis and Management of Female Urinary Incontinence: 73-79, 1993.
Petros and Ulmsten. The Intravaginal Slingplasty Procedure: IVS VI—Further Development of the “Double-Breasted” Vaginal Flap Repair—Attached Flap. Scand. J. Urol. Nephrol., Suppl. 153 An Integral Theory and its Method for the Diagnosis and Management of Female Urinary Incontinence: 81-84, 1993.
Petros and Ulmsten. The Posterior Fornix Syndrome: A Multiple Symptom Complex of Pelvic Pain and Abnormal Urinary Symptoms Deriving from Laxity in the Posterior Fornix of Vagina. Scand. J. Urol. Nephrol., Suppl. 153 An Integral Theory and its Method for the Diagnosis and Management of Female Urinary Incontinence: 89-93, 1993.
Petros and Ulmsten. The Role of a Lax Posterior Vaginal Fornix in the Causation of Stress and Urgency Symptoms: A Preliminary Report Acta Obstet. Gynecol. Scand., 69(Suppl. 153 An Integral Theory of Female Urinary Incontinence): 71-73, 1990.
Petros and Ulmsten. The Tethered Vagina Syndrome, Post Surgical Incontinence and I-Plasty Operation for Cure. Acta Obstet. Gynecol. Scand., 69(Suppl.153 An Integral Theory of Female Urinary Incontinence): 63-67, 1990.
Petros and Ulmsten. The Tuck Procedure: A Simplified Vaginal Repair for Treatment of Female Urinary Incontinence. Acta Obstet. Gynecol. Scand., 69(Suppl.153 An Integral Theory of Female Urinary Incontinence): 41-42, 1990.
Petros and Ulmsten. Urethral Pressure Increase on Effort Originates From Within the Urethra, and Continence From Musculovaginal Closure. Neurourology and Urodynamics, 14:337-350, 1995.
Petros, Peter E., et al. The Autogenic Ligament Procedure: A Technique for Planned Formation of an Artificial Neo-Ligament. Acta Obstet. Gynecol. Scand., 69(Suppl. 153 An Integral Theory of Female Urinary Incontinence):43-51, 1990.
Petros. Development of Generic Models for Ambulatory Vaginal Surgery—A Preliminary Report. Int. Urogynecol. J., 9:19-27, 1998.
Plaintiff Coloplast ,A/S's Opening Claim Construction Brief (Jan. 10, 2011) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV 10-227 BHS.
Plaintiff Coloplast A/S's Answer to Defendant Generic Medical Devices, Inc.'s Counterclaims (Mar. 22, 2010) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV10-227 BHS.
Plaintiff Coloplast A/S's Disclosure of Asserted Claims and Infringement Contentions (Jul. 6, 2010) Coloplast A/S, v. Generic Medical Devices, Inc., Court File No. CV '10-227 BHS.
Plaintiff's Reply to Counterclaim (Mar. 30, 2004) Mentor Corporation v. American Medical Systems, Inc. (Civ. No. 04-1000).
Product Monograph for Aris Transobturator Tape for the Treatment of Female Stress Urinary Incontinence, 2004, 40 pages.
Rackley, Raymond R., et al. Tension-free Vaginal Tape and Percutaneous Vaginal Tape Sling Procedures. Techniques in Urology, 7(2):90-100, 2001.
Rackley, Raymond. Synthetic Slings: Five Steps for Successful Placement—Follow These Steps to Insert Transvaginal/Percutaneous Slings Using Vaginal Approach Alone. Urology Times, 28:46-49, 2000.
Random House Webster's Unabridged Dictionary, 2001.
Raz, Shlomo, et al. The Raz Bladder Neck Suspension: Results in 206 Patients. The Journal of Urology: Urological Neurology and Urodynamics, 148:845-850, 1992.
Raz, Shlomo. Modified Bladder Neck Suspension for Female Stress Incontinence. Urology, 17(1):82-85, 1981.
Richardson, David A., et al. Delayed Reaction to the Dacron Buttress Used in Urethropexy. The Journal of Reproductive Medicine, 29(9):689-692, 1984.
Ridley, John H. Appraisal of the Goebell-Frangenheim-Stoeckel Sling Procedure. American Journal of Obstetrics and Gynecology, 95(5):714-721, 1966.
Sand et al., “Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles,” American Journal of Obstetrics & Gynecology vol. 184, Issue 7, pp. 1357-1364, Jun. 2001.
Schettini, M. et al., “Abdominal sacral colpopexy with prolene mesh,” Int Urogynecol J Pelvic Floor Dysfunct (1999) 10(5): 259-299.
Schumpelick, V. et at., “Minimized polypropylene mesh for preperitoneal net plasty (PNP) of incisional hernias,” Chirurg 70:422-430 (1999).
Shaw, W., “An Operation for the Treatment of Stress Incontinence,” Br. Med. J. 1949:1070-1073.
Sheiner et al., “An unusual complication of obturator foramen arterial bypass,” J. Cardiovasc. Surg., 1969, 10(4):324-328.
Sirls and Leach, “Use of Fascia Lata for Pubovaginal Sling,” Female Urology, 1996, Raz (ed.). W.B. Saunders Company, Chapter 32, pp. 376-381.
Sloan and Barwin, “Stress Incontinence of Urine: A Retrospective Study of the Complications and Late Results of Simple Suprapubic Suburethral Fascial Slings,” J. Urol., 1973, 110:533-536.
Solyx™ SIS System, The Carrier Tip That Allows for Advanced Control, (Accessed: Feb. 28, 2011).
Sottner et al. “New Single-Incision Sling System MiniArc™ in treatment of the female stress urinary incontinence” Gynekologicko-porodnická klinika [Online] 2010, 75(2), pp. 101-104.
Spencer et al., “A Comparison of Endoscopic Suspension of the Vesical Neck with Suprapubic Vesicourethropexy for Treatment of Stress Urinary Incontinence,” J. Urol., 1987, 137:411-415.
Spinosa, JP et al., Transobturator surgery for female stress incontinence: a comparative anatomical study of outside-in vs. inside-out techniques, BJU Intl., 100(5), pp. 1097-1102 (Nov. 2007).
Stamey, “Endoscopic Suspension of the Vesical Neck for Urinary Incontinence in Females,” Annals of Surgery, 1980, 192(4):465-471.
Stanton, Stuart L. Suprapubic Approaches for Stress Incontinence in Women. The Journal of the American Geriatrics Society, 38(3):348-351, 1990.
Staskin et al., “The Gore-tex sling procedure for female sphincteric incontinence: indications, technique, and results,” World J. Urol., 1997, 15:295-299.
Stothers et al., “Anterior Vaginal Wall Sling,” Female Urology, 1996, Raz (ed.), W.B. Saunders Company, Chapter 35, pp. 395-398.
Supplemental European Search Report issued in EP Application No. 03751825, Jun. 19, 2009, 5 pages.
Surgimesh Sling Treatment of Incontinence http://www.aspide.com Mar. 4, 2011.
Ulmsten and Petros, “Intravaginal Slingplasty (IVS): An Ambulatory Surgical Procedure for Treatment of Female Urinary Incontinence,” Scand. J. Urol. Nephrol., 1995, 29:75-82.
Ulmsten et al., “A three-year follow up of tension free vaginal tape for surgical treatment of female stress urinary incontinence,” Br. J. Obstet. Gynecol., 1999, 106:345-350.
Ulmsten et al., “An Ambulatory Surgical Procedure Under Local Anesthesia for Treatment of Female Urinary Incontinence,” Int. Urogynecol. J., 1996, 7:81-86.
Ulmsten et al., “Different Biochemical Composition of Connective Tissue in Continent and Stress Incontinent Women,” Acta Obstet. Gynecol. Scand., 1987, 66:455-457.
Related Publications (1)
Number Date Country
20180153672 A1 Jun 2018 US
Continuations (3)
Number Date Country
Parent 14740276 Jun 2015 US
Child 15883110 US
Parent 14151873 Jan 2014 US
Child 14740276 US
Parent 13402978 Feb 2012 US
Child 14151873 US
Continuation in Parts (1)
Number Date Country
Parent 12072901 Feb 2008 US
Child 13402978 US